MCID: RBL001
MIFTS: 56

Rubella

Categories: Eye diseases, Fetal diseases, Infectious diseases, Liver diseases, Neuronal diseases, Rare diseases, Reproductive diseases, Skin diseases

Aliases & Classifications for Rubella

Summaries for Rubella

MedlinePlus : 43 Rubella is an infection caused by a virus. It is usually mild with fever and a rash. About half of the people who get rubella do not have symptoms. If you do get them, symptoms may include A rash that starts on the face and spreads to the body Mild fever Aching joints, especially in young women Swollen glands Rubella is most dangerous for a pregnant woman's baby. It can cause miscarriage or birth defects. Rubella spreads when an infected person coughs or sneezes. People without symptoms can still spread it. There is no treatment, but the measles-mumps-rubella (MMR) vaccine can prevent it. Centers for Disease Control and Prevention

MalaCards based summary : Rubella, also known as german measles, is related to juvenile rheumatoid arthritis and mumps, and has symptoms including fever, headache and conjunctivitis. An important gene associated with Rubella is CD40LG (CD40 Ligand), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Bleomycin and Lactitol have been mentioned in the context of this disorder. Affiliated tissues include testes, heart and skin, and related phenotype is Increased shRNA abundance.

Disease Ontology : 12 A viral infectious disease that results in infection located in skin, has material basis in Rubella virus, which is transmitted by droplet spread of oronasal secretions from the infected person through coughing and sneezing, and transmitted by congenital method. The infection has symptom rash on the face which spreads to the trunk and limbs, has symptom fever, has symptom lymphadenopathy, has symptom joint pains, has symptom headache, and has symptom conjunctivitis.

CDC : 3 Rubella is a contagious disease caused by a virus. Most people who get rubella usually have a mild illness, with symptoms that can include a low-grade fever, sore throat, and a rash that starts on the face and spreads to the rest of the body. Rubella can cause a miscarriage or serious birth defects in a developing baby if a woman is infected while she is pregnant. The best protection against rubella is MMR (measles-mumps-rubella) vaccine.

Wikipedia : 75 Rubella, also known as German measles or three-day measles, is an infection caused by the rubella virus.... more...

Related Diseases for Rubella

Diseases in the Rubella family:

Congenital Rubella

Diseases related to Rubella via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 129, show less)
# Related Disease Score Top Affiliating Genes
1 juvenile rheumatoid arthritis 29.9 TNF HLA-DRB1 HLA-DPB1
2 mumps 29.5 TNF IL10RB IFNAR2 HLA-DRB1 HLA-DPB1
3 rheumatoid arthritis 28.0 TNF IL4 HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-B
4 measles 11.9
5 congenital rubella 11.9
6 microcephaly 11.4
7 limbic encephalitis with lgi1 antibodies 10.6 HLA-DRB1 HLA-DQB1
8 narcolepsy 2 10.6 HLA-DRB1 HLA-DQB1
9 autoimmune polyglandular syndrome type 3 10.6 HLA-DRB1 HLA-DQB1
10 hypersomnia 10.5 HLA-DRB1 HLA-DQB1
11 type ii mixed cryoglobulinemia 10.5 HLA-DRB1 HLA-DQB1
12 lichen planopilaris 10.5 HLA-DRB1 HLA-DQB1
13 metal allergy 10.5 HLA-DRB1 HLA-DQB1
14 recurrent respiratory papillomatosis 10.5 HLA-DRB1 HLA-DQB1
15 sporotrichosis 10.5 CD40LG CALM1
16 berylliosis 10.4 HLA-DRB1 HLA-DPB1
17 narcolepsy 1 10.4 MOG HLA-DRB1 HLA-DQB1
18 pediatric multiple sclerosis 10.4 MOG HLA-DRB1 HLA-DQB1
19 phenytoin or carbamazepine toxicity 10.4 HLA-B HLA-A
20 idiopathic inflammatory myopathy 10.4 HLA-DRB1 HLA-B
21 lichen sclerosus 10.4 HLA-DRB1 HLA-DQB1
22 microscopic polyangiitis 10.4 TNF HLA-DRB1
23 drug reaction with eosinophilia and systemic symptoms 10.4 TNF HLA-B
24 neuromyelitis optica 10.4 MOG HLA-DRB1 HLA-DPB1
25 myelitis 10.3 TNF MOG HLA-DPB1
26 whipple disease 10.3 HLA-DRB1 HLA-DQB1
27 htlv-1 associated myelopathy/tropical spastic paraparesis 10.3 HLA-B HLA-A
28 atrial tachyarrhythmia with short pr interval 10.3 HLA-B HLA-A
29 idiopathic achalasia 10.3 TNF HLA-DQB1
30 iridocyclitis 10.3 HLA-DPB1 HLA-B
31 tropical endomyocardial fibrosis 10.3 TNF IL4
32 endomyocardial fibrosis 10.3 TNF IL4
33 cataract 10.3
34 optic neuritis 10.3 TNF MOG HLA-DRB1
35 inflammatory bowel disease 25 10.3 TNF IL10RB
36 primary progressive multiple sclerosis 10.3 TNF MOG HLA-DRB1
37 idiopathic neutropenia 10.2 TNF HLA-DRB1 CD40LG
38 microscopic colitis 10.2 TNF HLA-DRB1 HLA-DQB1
39 demyelinating disease 10.2 TNF MOG CD40LG
40 sulfamethoxazole allergy 10.2 IL4 CD40LG
41 pure red-cell aplasia 10.2 HLA-DRB1 HLA-DQB1 HLA-A
42 cardiac sarcoidosis 10.2 TNF HLA-DQB1
43 echinococcosis 10.2 TNF HLA-DRB1 HLA-B
44 tungiasis 10.2 TNF IL4
45 celiac disease 1 10.2 HLA-DQB1 HLA-A CALR
46 encephalitis 10.1
47 postherpetic neuralgia 10.1 HLA-DRB1 HLA-B HLA-A
48 hemorrhagic fever with renal syndrome 10.1 TNF HLA-DRB1 HLA-B
49 retinitis pigmentosa 75 10.1 TNF IL10RB
50 pars planitis 10.1 HLA-DRB1 HLA-B HLA-A
51 autoimmune hepatitis 10.1 HLA-DRB1 HLA-DQB1 HLA-A
52 ocular cicatricial pemphigoid 10.1 IL4 HLA-DRB1 HLA-DQB1
53 sclerosing cholangitis 10.1 TNF HLA-DRB1 HLA-B
54 histoplasmosis 10.1 HLA-DRB1 HLA-B HLA-A
55 cholangitis 10.1 TNF HLA-DRB1 HLA-B
56 scleritis 10.1 TNF IL4
57 branchiootic syndrome 1 10.1
58 exanthem 10.1
59 vasculitis 10.1 TNF HLA-B CD40LG
60 acute disseminated encephalomyelitis 10.1 MOG HLA-DRB1 HLA-DQB1 HLA-B
61 neuritis 10.1 TNF MOG IL4
62 palindromic rheumatism 10.1 TNF HLA-DRB1 HLA-A
63 dengue shock syndrome 10.1 TNF HLA-DRB1 HLA-A
64 brucellosis 10.0 TNF IL4 CD40LG
65 autoimmune disease of musculoskeletal system 10.0 TNF IL4 CD40LG
66 narcolepsy 10.0 TNF MOG HLA-DRB1 HLA-DQB1
67 relapsing-remitting multiple sclerosis 10.0 TNF MOG IL4
68 hematopoietic stem cell transplantation 10.0 TNF HLA-B HLA-A
69 schistosomiasis 10.0 TNF IL4 CD40LG
70 anterior uveitis 10.0 HLA-B HLA-A
71 uveitis 10.0 TNF IL4 HLA-B
72 beryllium disease 10.0 TNF HLA-DRB1 HLA-DQB1 HLA-DPB1
73 chronic beryllium disease 10.0 TNF HLA-DRB1 HLA-DQB1 HLA-DPB1
74 trypanosomiasis 10.0 TNF IL4 CALR
75 severe cutaneous adverse reaction 10.0 TNF HLA-B HLA-A
76 primary systemic mycosis 10.0 TNF IL4 CALM1
77 oligoarticular juvenile idiopathic arthritis 10.0 TNF HLA-DRB1 HLA-DQB1 HLA-DPB1
78 connective tissue disease 10.0 TNF HLA-DRB1 HLA-DPB1 CD40LG
79 cytomegalovirus infection 10.0 TNF HLA-B HLA-A
80 myocarditis 10.0 TNF HLA-DQB1 HLA-B CD40LG
81 bone inflammation disease 10.0 TNF IL4 HLA-DRB1
82 psoriatic arthritis 10.0 TNF HLA-DRB1 HLA-B
83 chromoblastomycosis 10.0 IL4 HLA-A
84 purpura 9.9
85 chickenpox 9.9
86 rheumatic disease 9.9 TNF HLA-DRB1 HLA-B CD40LG
87 pulmonary tuberculosis 9.9 TNF IL4 HLA-DRB1
88 viral infectious disease 9.9 TNF IL4 CD40LG
89 bare lymphocyte syndrome, type ii 9.9 TRIM22 HLA-DQB1 HLA-A
90 pityriasis rosea 9.9 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
91 idiopathic bronchiectasis 9.9 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
92 paraneoplastic pemphigus 9.9 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
93 vogt-koyanagi-harada disease 9.9 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
94 opisthorchiasis 9.9 TNF IL4
95 chronic pyelonephritis 9.9 HLA-B HLA-A
96 immune system disease 9.9 TNF MOG IL4 CALR
97 toxoplasmosis 9.8 TNF IL4 HLA-DQB1 CD40LG
98 colitis 9.8 TNF IL4 IL10RB
99 autoimmune disease of central nervous system 9.8 TNF MOG IL4 HLA-DRB1
100 cytomegalovirus retinitis 9.8 TNF HLA-DQB1 HLA-B HLA-A
101 meningoencephalitis 9.8
102 thyroiditis 9.8
103 herpes zoster 9.8
104 scarlet fever 9.8
105 cold agglutinin disease 9.8
106 growth hormone deficiency 9.8
107 actinic prurigo 9.8 TNF HLA-DRB1
108 leishmaniasis 9.8 TNF IL4 HLA-DRB1 HLA-DQB1
109 nontuberculous mycobacterial lung disease 9.8 TNF HLA-DRB1 HLA-B HLA-A
110 alveolar echinococcosis 9.8 TNF HLA-DRB1 HLA-B HLA-A
111 dengue hemorrhagic fever 9.7 TNF HLA-DRB1 HLA-B HLA-A
112 rheumatic heart disease 9.7 TNF IL4 HLA-DRB1 HLA-B
113 diabetes mellitus, insulin-dependent 9.7 IL4 HLA-DRB1 HLA-DQB1 HLA-A
114 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 9.6 TRIM5 IL4 CD40LG
115 aphthous stomatitis 9.6 TNF IL4 HLA-B HLA-A
116 spondyloarthropathy 9.6 TNF IL4 HLA-B HLA-A
117 multiple sclerosis 9.5 TNF MOG IL4 HLA-DRB1 HLA-DQB1
118 geographic tongue 9.5 TNF HLA-DRB1 HLA-DQB1 HLA-B HLA-A
119 panuveitis 9.5 TNF HLA-DRB1 HLA-DQB1 HLA-B HLA-A
120 takayasu arteritis 9.5 TNF HLA-DRB1 HLA-DPB1 HLA-B HLA-A
121 autoimmune disease 9.3 TNF MOG IL4 HLA-DRB1 HLA-DQB1 CD40LG
122 aplastic anemia 9.2 TNF IL4 HLA-DRB1 HLA-B HLA-A
123 glaucomatocyclitic crisis 9.2 TNF HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-B HLA-A
124 graft-versus-host disease 9.2 TNF HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-B HLA-A
125 asthma 9.2 TNF IL4 HLA-DRB1 HLA-DQB1 HLA-DPB1 CD40LG
126 diabetes mellitus 9.2 TNF HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-B HLA-A
127 human immunodeficiency virus type 1 9.1 TRIM5 TNF HLA-B HLA-A
128 malaria 9.0 TNF IL4 HLA-DRB1 HLA-B HLA-A CD40LG
129 systemic lupus erythematosus 9.0 TNF IL4 HLA-DRB1 HLA-DQB1 HLA-DPB1 CD40LG

Graphical network of the top 20 diseases related to Rubella:



Diseases related to Rubella

Symptoms & Phenotypes for Rubella

Symptoms:

12 (showing 6, show less)
  • fever
  • headache
  • conjunctivitis
  • lymphadenopathy
  • rash on the face which spreads to the trunk
  • joint pains

UMLS symptoms related to Rubella:


fever, pruritus, exanthema

GenomeRNAi Phenotypes related to Rubella according to GeneCards Suite gene sharing:

26 (showing 1, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance GR00327-A 8.92 HLA-B HLA-DPB1 HLA-DQB1 IL4

Drugs & Therapeutics for Rubella

Drugs for Rubella (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 84, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
2
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
3 Liver Extracts Phase 4
4 Immunologic Factors Phase 4
5 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
6 Gastrointestinal Agents Phase 4
7 Cathartics Phase 4
8 Laxatives Phase 4
9 Vaccines Phase 4
10 Anti-Bacterial Agents Phase 4
11 insulin Phase 4
12 Insulin, Globin Zinc Phase 4
13 Antibiotics, Antitubercular Phase 4
14 Antiviral Agents Phase 4
15
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
16
Aluminum hydroxide Approved, Investigational Phase 3 21645-51-2
17
Petrolatum Approved, Investigational Phase 3 8009-03-8
18
Podophyllin Approved Phase 3 9000-55-9
19
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
20 Estrogens Phase 3
21 Progestins Phase 3
22 Steroid Synthesis Inhibitors Phase 3
23 Hormones Phase 3
24 Hormone Antagonists Phase 3
25 Estrogen Receptor Antagonists Phase 3
26 Estrogen Antagonists Phase 3
27 Aromatase Inhibitors Phase 3
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
29 Hemagglutinins Phase 3
30 taxane Phase 3
31 Somatomedin B Phase 3
32 PENTA Phase 3
33 Micronutrients Phase 3
34 Trace Elements Phase 3
35 Antioxidants Phase 3
36 retinol Phase 3
37 Vitamins Phase 3
38 Protective Agents Phase 3
39 Retinol palmitate Phase 3
40 Nutrients Phase 3
41 Antineoplastic Agents, Phytogenic Phase 3
42 Keratolytic Agents Phase 3
43 Dermatologic Agents Phase 3
44
Altretamine Approved Phase 2 645-05-6 2123
45
Aluminum sulfate Approved Phase 1, Phase 2 10043-01-3
46 Fibrinolytic Agents Phase 2
47 Anticoagulants Phase 2
48 Aluminum phosphate Phase 1, Phase 2
49 Pharmaceutical Solutions Phase 2
50 Immunoglobulin G Phase 1
51 Immunoglobulin M Phase 1
52 Autoantibodies Phase 1
53
Mercaptopurine Approved 50-44-2 667490
54
Methotrexate Approved 1959-05-2, 59-05-2 126941
55
Certolizumab pegol Approved 428863-50-7
56
Adalimumab Approved 331731-18-1 16219006
57
Infliximab Approved 170277-31-3
58
Azathioprine Approved 446-86-6 2265
59
Hydroxocobalamin Approved 13422-51-0 11953898 15589840
60
Oxytocin Approved, Vet_approved 50-56-6 439302 53477758
61
Eugenol Approved 97-53-0 3314
62
Hyaluronic acid Approved, Vet_approved Early Phase 1 9004-61-9 53477741
63
Iron Approved, Experimental 15438-31-0, 7439-89-6 23925 27284
64
Cyanocobalamin Approved, Nutraceutical 68-19-9 44176380
65
Cobalamin Experimental 13408-78-1 6857388
66 Acidophilus
67 Analgesics, Opioid
68 Anti-HIV Agents
69 Anti-Retroviral Agents
70 Vitamin B 12
71 Vitamin B12
72 Oxytocics
73 Caryophyllene
74 Disinfectants
75 Chlorhexidine gluconate
76 Anti-Infective Agents, Local
77 Sweet Basil
78 Anti-Inflammatory Agents
79 Holy Basil
80 Antibodies
81 Adjuvants, Immunologic Early Phase 1
82 Immunoglobulins
83 Hylan Early Phase 1
84 Viscosupplements Early Phase 1

Interventional clinical trials:

(showing 155, show less)
# Name Status NCT ID Phase Drugs
1 Assessing Immunogenicity of Measles-Rubella Vaccine at 6 and 9 Months of Age Unknown status NCT03071575 Phase 4
2 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts : a Randomized Controlled Trial Unknown status NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
3 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
4 Induction and Maintenance of Immunity Against Measles in Pediatric Orthotopic Liver Transplantation Recipients: a Prospective Nationwide Study in Switzerland Unknown status NCT01770119 Phase 4
5 Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children Completed NCT03680417 Phase 4
6 Blinded, Randomised Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-mumps-rubella-varicella Candidate Vaccine When Given to Healthy Children in Their Second Year of Life Completed NCT00126997 Phase 4
7 Phase IV Open Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-Mumps-Rubella (MMR) Vaccine When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Completed NCT00388440 Phase 4
8 Non-interference and Safety of Concomitant Administration of Measles-rubella and Rotavirus Vaccines at 9 Months of Age in Rural Bangladesh Completed NCT01700621 Phase 4
9 A Double-blind, Randomised, Controlled, Multi-centre Safety Study of a Refrigerator-stable Formulation of VARIVAX® in Healthy 12 to 15 Month-old Infants. Completed NCT00432731 Phase 4
10 Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines in Children Under 2 Years Old in Argentina Completed NCT03368495 Phase 4
11 Immunogenicity and Safety of Concurrent Administration of Live, Attenuated SA 14-14-2 Japanese Encephalitis Vaccine and Measles-Mumps-Rubella Vaccine in Infants 9-12 Months of Age in the Philippines Completed NCT02880865 Phase 4
12 Immunogenicity and Safety of AVAXIM™ 80U-Pediatric Administered Alone or Concomitantly With TRIMOVAX™ in 12-13 Months Old Healthy Hepatitis A Seronegative Turkish Children Completed NCT00313950 Phase 4
13 An Open, Randomized, Multicenter Study of the Safety, Tolerability, & Immunogenicity of VAQTA™ Given Concomitantly With PROQUAD™ and PREVNAR™ in Healthy Children 12 Months of Age Completed NCT00312858 Phase 4
14 An Open, Multicenter Study of the Safety and Tolerability of VAQTA(TM) and ProQuad(TM) in Healthy Children 12 to 23 Months of Age Completed NCT00326183 Phase 4
15 Multicenter Randomized Clinical Trial in Patients With Juvenile Idiopathic Arthritis: Safety and Efficacy of Vaccination With Live Attenuated Measles, Mumps, Rubella Vaccine Completed NCT00731965 Phase 4
16 Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella), Single Dose and Multidose Presentations in Children 12 to 23 Months of Age. Completed NCT01777529 Phase 4
17 Seroprevalence of Antibodies to Measles, Mumps, and Rubella, and Serologic Responses After Vaccination Among Human Immunodeficiency Virus (HIV)-1 Infected Adults in Northern Thailand Completed NCT02724852 Phase 4
18 Comparison of Immunization Schedules of Beijing Tiantan Biological's MMR Vaccine in 18-72 Month-Old Children Completed NCT03160820 Phase 4
19 Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With a Combined Measles-mumps-rubella (MMR) Vaccine Completed NCT02325310 Phase 4
20 A Phase 4, Randomized Trial to Assess the Safety and Immunogenicity of Inactivated Poliovirus Vaccine When Given Concomitantly With Measles and Rubella Combined Vaccine and Yellow Fever Vaccine at Nine Months and When Administered Via Different Vaccination Routes Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
21 Immunogenicity of Co-administration of Measles Containing Vaccine and Japanese Encephalitis Alive Vaccines Completed NCT02643433 Phase 4
22 A Phase IV, Non-Inferiority, Observer Blind Randomized Clinical Study Comparing Safety And Immunogenicity Of MMR Subcutaneous Vaccination By Disposable-Syringe Jet Injector To Vaccination By Needle And Syringe For The Administration In Healthy Children In India Aged 15 To 18 Months Completed NCT02253407 Phase 4
23 Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine After Concomitant Vaccination in ≥50-year-old Adults Completed NCT03552445 Phase 4
24 The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection Completed NCT03453801 Phase 4
25 Double-Blind Placebo-Controlled Clinical Effectiveness Trial of the 23-Valent Pneumococcal Vaccine Among Military Trainees At Increased Risk of Respiratory Disease Completed NCT02079701 Phase 4
26 A Randomised Controlled Trial Comparing Two-Dose Priming With the 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks to 6 and 14 Weeks in Nepali Children Completed NCT02385513 Phase 4
27 A Single Centre, Open-label, Randomised Clinical Study to Investigate Meningococcal Serogroup A and C Saccharide Specific B Cell Responses in Adult Volunteers to One of Three Regimens of Meningococcal ACWY Conjugate Vaccine or Meningococcal ACWY Polysaccharide Vaccine Priming Doses Followed by a Booster Dose of the Meningococcal ACWY Conjugate Vaccine Completed NCT01593514 Phase 4
28 Measles-mumps-rubella Vaccine at 6 Months of Age, Immunology, and Childhood Morbidity in a High-income Setting Recruiting NCT03780179 Phase 4
29 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination (Version IV Dated 24Oct2017) Recruiting NCT03350698 Phase 4
30 Evaluating Immunogenicity and Safety Effect on Combined Immune Effect of EV71 Inactivated Vaccine and HepB、MPSV-A、MR、JE-L:A Multi-center Randomized Controlled Trial Recruiting NCT03519568 Phase 4
31 The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts Not yet recruiting NCT03477448 Phase 4 Bleomycin;Purified Protein Derivative
32 Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants Unknown status NCT01763268 Phase 2, Phase 3
33 Effect of Acupuncture Pre-treatment Combined With Letrozole on Live Birth in Infertile Women With Polycystic Ovary Syndrome Unknown status NCT02491320 Phase 3 Letrozole
34 A Comparison of the Safety, Tolerability, and Immunogenicity of a Refrigerator-Stable Measles, Mumps, Rubella, and Varicella Combination Vaccine V221 (Refrigerated) Versus V221 (Frozen) in Healthy Children Completed NCT00092430 Phase 3
35 Blinded, Randomized Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Measles-mumps-rubella-varicella Candidate Vaccine Given to Healthy Children During the Second Year of Life Completed NCT00127010 Phase 3
36 A Phase III Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP) Completed NCT01536405 Phase 3
37 Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Completed NCT00751348 Phase 3
38 Immunogenicity and Safety Study of GlaxoSmithKline Biological's Live Attenuated Measles Mumps Rubella Varicella Vaccine (PriorixTetra™) When Co-administered With Conjugated Meningococcal C Vaccine (Meningitec®, Nuron Biotechs' Vaccine) in Healthy Children Completed NCT01506193 Phase 3
39 Blinded, Randomised, Controlled Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Combined Measles-mumps-rubella-varicella Candidate Vaccine Given to Healthy Children in Their Second Year of Life Completed NCT00127023 Phase 3
40 An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of V221 Given Concomitantly With Pneumococcal Conjugate Vaccine in Healthy Children 12 to 15 Months of Age Completed NCT00109343 Phase 3
41 Follow-up to Evaluate the the Immunogenicity & Safety of GSK Biologicals' MMRV Vaccine Given as a Two-dose Schedule in the Second Year of Life, as Compared to Separate Administration of GSK Biologicals' Priorix® & Varilrix®. Completed NCT00406211 Phase 3
42 A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity of MMRV Vaccine When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine to Healthy Toddlers Completed NCT00626327 Phase 3
43 An Open-label, Multi-centre Study of the Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) Manufactured With Recombinant Human Albumin (rHA) When Administered to Children in Their Second Year of Life Completed NCT00560755 Phase 3
44 An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of ProQuad® When Administered by Intramuscular (IM) Route or Subcutaneous (SC) Route to Healthy Children Aged 12 to 18 Months Completed NCT00402831 Phase 3
45 Immunogenicity and Safety of Japanese Encephalitis Chimeric Virus Vaccine (JE CV) Concomitantly Administered With Measles, Mumps, and Rubella (MMR) Vaccine in Toddlers in Taiwan. Completed NCT01188343 Phase 3
46 Immunogenicity & Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) Co-administered With Merck & Company, Inc. Measles-Mumps-Rubella Vaccine (M-M-RII) & Merck & Co Varicella Vaccine (VARIVAX™) to Children 15 Months of Age Completed NCT00197015 Phase 3
47 A Pilot Study to Compare the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine and the Concomitant Administration of the Currently Licensed VARIVAX™ and M-M-R II™ in Healthy Children Completed NCT00975507 Phase 3
48 Administration of Frozen Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine to Healthy Children at 4 to 6 Years of Age Completed NCT00985166 Phase 3
49 Comparison of the Safety, Tolerability, and Immunogenicity of 3 Consistency Lots of Frozen Measles, Mumps, Rubella, and Varicella Vaccine (ProQuad) in Healthy Children Completed NCT00985153 Phase 3
50 Open, Multicenter, Randomised, Controlled Phase IIIb Study Evaluating the Immunogenicity and Safety of Subcutaneous Versus Alternative Administration Route of Combined MeMuRu-OKA Vaccine to Healthy Children Aged 11 to 21 Months. Completed NCT00351923 Phase 3
51 Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Four to Six Years of Age (209762) Completed NCT01621802 Phase 3
52 Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Seven Years and Older (209762) Completed NCT02058563 Phase 3
53 Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine Completed NCT00226499 Phase 3
54 An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of Concomitant Versus Separate Administration of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) and a Booster Dose of Infanrix® Hexa in Healthy Children 12 to 23 Months of Age Completed NCT00432042 Phase 3
55 Safety Study of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered With Other Pediatric Vaccines to Healthy Toddlers Completed NCT00483574 Phase 3
56 A Study of M-M-R(TM) II at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age Completed NCT00092391 Phase 3
57 A Randomized, Placebo-Controlled, Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, (MMRIIÒ) and Varicella (VARIVAXÒ) Vaccines Administered Concurrently to Healthy Children (AV018) Completed NCT00192491 Phase 3
58 Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. Completed NCT01991899 Phase 3
59 Randomized, Controlled Clinical Trial for Measles - Rubella Combined Vaccine (MRVAC) Produced by POLYVAC by Technology Transfer From Japan (Phase III) Completed NCT03713359 Phase 3
60 An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers Completed NCT00422292 Phase 3
61 An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of M-M-R™II Manufactured With Recombinant Human Albumin (rHA) and VARIVAX® When Administered Concomitantly by Intramuscular (IM) Route or Subcutaneous (SC) Route at Two Separate Injection Sites in Healthy Subjects 12 to 18 Months of Age Completed NCT00432523 Phase 3
62 Consistency Study of GSK Biologicals' Measles-mumps-rubella (MMR) Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Healthy Children 12 to 15 Months of Age Completed NCT01702428 Phase 3
63 Safety and Immunogenicity Study of GSK Biologicals' Measles-mumps-rubella (MMR) Vaccine (209762) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine, in Healthy Children 12 to 15 Months of Age Completed NCT02184572 Phase 3
64 An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of Frozen MMRV Given Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines in Healthy Children 12 to 15 Months of Age Completed NCT00984295 Phase 3
65 An Immunogenicity and Safety Evaluation of Two Doses of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) Given to Healthy Subjects at 9 and 12 Months of Age Completed NCT00384397 Phase 3
66 A Phase IIIb, Open, Randomised, Multicentre, Primary Study in Healthy Children, to Establish the Non-inferiority of GlaxoSmithKline (GSK) Biologicals' MeMuRu-OKA Vaccine (Administered at 9 and 15 Months of Age) Versus Priorix™ (9 Months of Age) and Priorix™ Co-administered With Varilrix™ at 15 Months of Age (Comparator) and Also to Evaluate the Non-inferiority of Priorix™ (9 Months of Age) and MeMuRu-OKA Vaccine (15 Months of Age) Versus the Comparator, All Administered Subcutaneously as Two-dose Primary Vaccination Course Completed NCT00969436 Phase 3
67 An Open-label, Randomised, Comparative, Multi-centre Study of the Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA Administered to Healthy Children From 9 Months of Age Completed NCT00566527 Phase 3
68 A Phase 3, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Passage Extension 34 (PE34) Process Administered Concomitantly With M-M-R™ II Completed NCT03239873 Phase 3
69 A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II Completed NCT02062502 Phase 3
70 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Other Pediatric Vaccines in Healthy Toddlers Completed NCT03205371 Phase 3
71 Immunogenicity and Safety Study of GSK Biologicals' Priorix Vaccine (209762) at an End of Shelf-life Potency Compared to Merck & Co., Inc.'s Measles-mumps-rubella (MMR) Vaccine When Both Are Given on a 2-dose Schedule to Healthy Children in Their 2nd Year of Life Completed NCT01681992 Phase 3
72 Study to Evaluate the Safety, Reactogenicity & Immunogenicity of a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™, vs Hib-MenC or Priorix™ Only, in Toddlers (13-14 m) Primed With 3 Doses of Hib (as Part of a DTPa -Containing Vaccine) & MenC-CRM197 Conjugate Vaccines. Completed NCT00263653 Phase 3
73 Immunogenicity and Safety Study of Kinrix® Co-administered With Varivax® Completed NCT00871117 Phase 3
74 A Phase 3b, Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants Completed NCT00806195 Phase 3
75 A Phase III Randomised, Open, Controlled Study to Assess the Safety and Immunogenicity of Concomitant Administration of Virosomal Hepatitis A Vaccine (Epaxal®) With DTPaHibIPV, OPV and MMR Vaccines vs. Non-concomitant Administration in 12-15 Month Old Children. Follow-up: Serological Long-term Follow-up of Subjects for up to 42 Months, 5.5 and 7.5 Years After the Second Dose. Completed NCT01307436 Phase 3
76 A Phase III Open-label Randomised Study, to Evaluate the Immunogenicity and Safety of the Concomitant Administration of V419 (PR5I) Given at 2, 3 and 4 Months of Age With Two Types of Meningococcal Serogroup C Conjugate (MCC) Vaccines Given at 3 and 4 Months of Age, and Followed by the Administration at 12 Months of Age of a Combined Haemophilus Influenzae Type b-MCC Vaccine Completed NCT01553279 Phase 3
77 COMPAS: A Phase III Study to Demonstrate Efficacy of GSK Biologicals' 10-valent Pneumococcal Vaccine (GSK1024850A) Against Community Acquired Pneumonia and Acute Otitis Media Completed NCT00466947 Phase 3
78 Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age Completed NCT01346293 Phase 3
79 A Phase III, Randomized, Multinational Study, Double-blinded for the Immunogenicity and Consistency Evaluation of 3 Hib-MenCY-TT Vaccine Lots and Single-blinded and Controlled for the Evaluation of Safety and Immunogenicity of GSK Biologicals' Haemophilus Influenzae Type b and Neisseria Meningitidis Serogroups C and Y-tetanus Toxoid Conjugate Vaccine Combined (Hib-MenCY-TT) Compared to Monovalent Hib Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age. Completed NCT00289783 Phase 3
80 A Phase II / III, Clinical Trial to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella, Produced by Bio-Manguinhos / Fiocruz in 11-month-old Infants. Recruiting NCT03148990 Phase 2, Phase 3
81 Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe Recruiting NCT03547271 Phase 3
82 Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever Vaccines Followed by a Booster of the Malaria Vaccine. Active, not recruiting NCT02699099 Phase 3
83 A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13™ With Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION) Active, not recruiting NCT03620162 Phase 3
84 The Efficacy of Intralesional Measles, Mumps, Rubella (MMR) Vaccine, Intralesional Candidal Antigen and Topical Podophyllin in Treatment of Genital Warts: A Comparative Study Not yet recruiting NCT03853785 Phase 3 Topical Podophyllin
85 A Multicenter, Randomized, Open-Label Study to Compare the Immunogenicity, Safety, and Tolerability of Measles, Mumps, Rubella, and Varicella of Combination Vaccine ProQuad With Concomitant Administration of M-M-R II and VARIVAX in Healthy Korean Children Terminated NCT00839917 Phase 3
86 Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds Completed NCT00892775 Phase 2
87 A Comparison of the Safety, Tolerability, and Immunogenicity of V205C Manufactured With Recombinant Human Albumin (rHA) Versus V205C Manufactured With Pooled-Donor Human Serum Albumin (HSA) in Healthy Children 12 to 18 Months of Age Completed NCT00092404 Phase 2
88 Comparative Study Evaluating the Immunogenicity and Safety of MeMuRu-OKA Vaccine and Measles-mumps-rubella Vaccine (Priorix™) Co-administered With Varicella Vaccine (Varilrix™) in Children Primed With Measles-mumps-rubella Vaccine Completed NCT00353288 Phase 2
89 Comparative Study Evaluating the Immunogenicity & Safety of MeMuRu-OKA Vaccine & Measles-mumps-rubella Vaccine (Priorix™) Co-administered With Varicella Vaccine (Varilrix™) in Children Primed With Both Measles-mumps-rubella & Varicella Vaccines Completed NCT00352898 Phase 2
90 Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months Completed NCT00192166 Phase 2
91 A Phase II, Randomized, Observer Blind, Controlled, Multicenter Study to Assess Immunogenicity and Antibody Persistence Following Vaccination With GSK's Candidate Combined Measles, Mumps, and Rubella Vaccine (MMR) Versus M-M-R® II as a First Dose, Both Administered Subcutaneously at 12-15 Months of Age, Concomitantly With Hepatitis A Vaccine (HAV), Varicella Vaccine (VV) and Pneumococcal Conjugate Vaccine (PCV) But at Separate Sites. Completed NCT00861744 Phase 2
92 Immunogenicity of GlaxoSmithKline Biologicals' MMRV Vaccine (208136) vs. ProQuad®, When Coadministered With Hepatitis A and Pneumococcal Conjugate Vaccines to Children 12-14 Months of Age. Completed NCT00578175 Phase 2
93 A Dose Selection Study in Healthy Children Comparing Measles Mumps, Rubella, and Varicella (ProQuad) Vaccine to M-M-R II Given Concomitantly With Process Upgrade Varicella Vaccine (PUVV) in Separate Injections Completed NCT00986232 Phase 2
94 A Comparison of the Safety, Tolerability, and Immunogenicity of V205C Manufactured From the 2003 Measles Stock Seed With Recombinant Human Albumin (rHA) Versus Currently Licensed V205C Manufactured From the 1967 Measles Stock Seed With Human Serum Albumin (HSA) in Healthy Children 12 to 18 Months of Age Completed NCT00109278 Phase 2
95 A Simulated Vaccine Efficacy Trial Using MMR and Tdap-IPV Vaccines in Healthy, HIV Negative Women at High Risk of HIV Infection in Lusaka and Ndola, Zambia. Completed NCT02589678 Phase 1, Phase 2
96 A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group Completed NCT00000815 Phase 2
97 Phase 2 Study of a Live Attenuated Measles Virus-Vectored Chikungunya Vaccine in a Previously Epidemic Area Completed NCT03101111 Phase 2
98 A Multicentre Primary & Booster Vaccination Study of GSK Biologicals' Hib-MenCY-TT Conjugate Vaccine vs ActHIB® & MenC Conjugate Licensed Vaccine When Given According to the 2-4-6 Month Schedule to Healthy Infants With Booster Dose at 12 to 15 Months Completed NCT00134719 Phase 2
99 Double Blinded, Randomized, Priorix®- and Placebo-controlled, Trial to Evaluate the Optimal Dose of MV-CHIK Vaccine (Against Chikungunya Virus) in Regard to Immunogenicity, Safety and Tolerability in Healthy Volunteers Completed NCT02861586 Phase 2
100 An Investigation Into the Effectiveness of NAET on Autism Spectrum Disorders Completed NCT00247156 Phase 1, Phase 2
101 A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants Completed NCT02308540 Phase 1, Phase 2
102 A Phase II, Randomized, Dose-scheduling, Observer-Blinded Study to Assess the Safety, Reactogenicity and Immunogenicity of Vi-DT Conjugate Vaccine in 6-23-Month Old Healthy Filipino Infants and Toddlers Active, not recruiting NCT03527355 Phase 2
103 A Phase 2 Randomized, Double-Blind, Controlled Trial of the Safety and Immunogenicity of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso Active, not recruiting NCT03614533 Phase 2
104 Immunogenicity and Safety of Live Attenuated Varicella Vaccine in 12 and 18 Month-old Children, With and Without Concomitant Administration of Measles-Mumps-Rubella Vaccine Terminated NCT00258726 Phase 1, Phase 2
105 Antibodies Screening in Multiple Sclerosis as a Part of an International Survey in Autoimmune Diseases. Unknown status NCT00230204 Phase 1
106 A Phase I, Open, Uncontrolled Study, to Evaluate the Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella in Young Adults Completed NCT02196285 Phase 1
107 Measles-mumps-rubella and Measles-mumps-rubella-varicella Vaccines: Effect of Age at First Dose on Safety and Immunogenicity of the Measles Component. Unknown status NCT02712203
108 The Influence of Probiotics on the Immunologic Response to Vaccinations in Infants Unknown status NCT00645996
109 Phase I Study for Positive IgM Antibody Detection in New Diagnostic Test Kit for for Acute Phase Infection Unknown status NCT01646411
110 Ontogeny of Vaccine-Induced Measles Immunity Child Participant-6 and 9 Months Unknown status NCT00240916
111 Seroimmunity 2007. Serological Study of the Swedish Population Regarding Vaccine Preventable Diseases Within the National Immunization Program (NIP), and a Sub Study Focusing on Foreign Born 14-16 Year-Olds. Unknown status NCT00932269
112 Clinical Characteristics and Genetic Profiles of Severe Combined Immunodeficiency in China Unknown status NCT02231983
113 Bioarray Compilation for the Serological Assessment of Immunity Against Vaccine-preventable Infections of Available Prophylaxis in Refugees and Immigrants Unknown status NCT03107312
114 Impact of Particulate Matter on Mothers and Babies in Antwerp (IPANEMA), a Prospective Cohort Study on the Impact of Pollutants and Particulate Matter in Pregnancy: Methodology and Design Unknown status NCT02592005
115 Comparison Between Clinical and MRI Multiple Sclerosis Activity and Expression of Human Endogenous Retrovirus Type W and Herpesvirus in Peripheral Blood of Patients Unknown status NCT02489877
116 Cross Sectional Study of Vaccine Antibody Response in Inflammatory Bowel Disease Patients Completed NCT02434133
117 Duration of Long-Term Immunity After Hepatitis B Virus Immunization Completed NCT01182311
118 Study of Rubella Immunity. Response to Vaccination of Subjects With Very Low, Equivocal or Undetectable Titers of Rubella Virus Antibodies Completed NCT02934295
119 Rubella Susceptibility in Multiparous Women Completed NCT00401505
120 Freeze-dried Live Attenuated Measles and Rubella Combined Vaccine "Takeda" Specified Drug-use Survey of Vaccinees After the Second Vaccination Completed NCT02158364 Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
121 Freeze-dried Live Attenuated Measles and Rubella Combined Vaccine "Takeda" Special Drug Use Surveillance of Vaccinees After the First Vaccination Completed NCT02151773 Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
122 A Serological Study of Measles, Mumps and Rubella in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella) in Health Centers Where a Phase III Study Should be Conducted Completed NCT01874457
123 Persistence of Humoral and Cellular Immune Responses Following Age-appropriate Vaccination With the MMR Vaccine Completed NCT00962819
124 Vaccination Rates in Obstetric Opioid-Addicted Patients Completed NCT03039725
125 Evaluation of the Immunogenicity of Pneumococcal Conjugate Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Treated With Highly Active Antiretroviral Therapy (HAART) Completed NCT00013871
126 Developing a Computer-based Intervention That Provides Individually-tailored Educational Information for MMR Vaccine-hesitant Parents Completed NCT01369394
127 A Prospective, Multisite Study to Evaluate the Impact of Measles, Mumps, Rubella and Varicella ProQuad® Vaccination in Pediatric Patients 6-24 Months of Age Who Are Being Considered and/or Evaluated for Any Solid Organ Transplant Completed NCT02687763 Early Phase 1
128 Altruistically Framed Messages and Impact on Parents' Reported Willingness to Immunize Their Children Completed NCT02015689
129 Environmental Factors in the Etiology of Autism Completed NCT00106652
130 Examining Adolescent Assessment, Feedback, Incentive, and Exchange (AFIX) Completed NCT01544764
131 Interaction Between Meningococcal Serogroup B Vaccine (Bexsero™) and Routine Infant Vaccines on the Risk of Occurrence and Recurrence of Adverse Events Following Immunization. Completed NCT02712177
132 Evaluation of Immunologic Memory Following Pneumococcal, Hepatitis B, and Measles Vaccination in HIV Infected Children Treated With Highly Active Antiretroviral Therapy (HAART) Completed NCT00257127
133 Iridocorneal Angle and Anterior Segment Structure in Pediatric Cataract Completed NCT03778086
134 HBIG for Prevention of Mother-to-infant HBV Transmission Completed NCT02312531 Hepatitis B immunoglobulin
135 An Observational Study of Children Immunised in Infancy Against Hepatitis B Virus, Evaluating the Persistence of Immunity and the Immune Response to a Scheduled Booster Dose of Hepatitis B Vaccine Completed NCT00873652
136 Nasal Oxcytocin Fails to Increase Pregnancy Rate of IUI Completed NCT00805662 oxytocin, placebo
137 Comparison of Constraint-induced Movement Therapy and Its Modified Form on Upper Motor Function Outcomes and Psychosocial Impact in Hemiplegic Cerebral Palsy. Completed NCT03691506
138 Efficacy of Ocimum Sanctum as a Pre-procedural Mouth Rinse in Reducing Aerosol Contamination Produced by Ultrasonic Scaler: a Clinical and Microbiological Study. Completed NCT03839719
139 A Pragmatic Trial to Quantitatively and Qualitatively Assess Different Techniques for the ID Administration of Fractional Dose IPV in a Campaign Setting in The Gambia Completed NCT02967783
140 Evaluation of the Acrysof Toric SN60T3 Intraocular Lens in Patients With Predicted Residual Corneal Astigmatism Between 0.75 and 1.00 D. Completed NCT00542581
141 Surveillance of Zika-related Microcephaly in Sub-Saharan Africa and Asia Recruiting NCT03922594
142 Study of the Vaccination Coverage and Level of Protection Against Vaccine-preventable Infectious Diseases in Pediatric and Adult Risk Patients in a University Hospital Recruiting NCT03820752
143 Study on Compliance, Safety and Effectivity of Vaccination for Children With Hematologic Malignancies or Solid Tumors and Their Parents Recruiting NCT03373656
144 Vaccines Immunogenicity in Children Transplanted or Candidate for a Renal, Hepatic, Cardiac or Pulmonary Transplantation, Followed in the Rhône-Alpes Region. A Descriptive and Prospective Monocentric Cohort Study Recruiting NCT03180359
145 Potency of Allogenic Umbilical Cord Mesenchymal Stem Cells for Osteoarthritis Management Recruiting NCT03800810 Early Phase 1 Hyaluronic Acid
146 Intestinal Response Patterns to Microbial Signals in the Healthy Rural & Urban and in the Crohn's Disease Host Gut Recruiting NCT03872622
147 Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment: Cohort Study in Fiocruz/IFF Recruiting NCT03255369
148 EVERREST - Developing a Therapy for Fetal Growth Restriction. A 6 Year Prospective Study to Define the Clinical and Biological Characteristic of Pregnancies Affected by Severe Early Onset Fetal Growth Restriction. Recruiting NCT02097667
149 Targeted Vaccination of Children in Urban Slums Against Cholera: Evaluation of a Potentially Cost-effective and Impactful Strategy for Deploying Oral Cholera Vaccine in Bangladesh Active, not recruiting NCT02727855
150 Screening For Critical Congenital Anomalies In NICU And Their Out Come in Assiut Universty Not yet recruiting NCT03882385
151 Clinical Audit On Management Of Congenital Heart Disease In Assiut Children University Hospital Not yet recruiting NCT03850223
152 Association Between Autism and Iron Deficiency in Children Diagnosed Autism Not yet recruiting NCT03601468
153 MMR and Varicella Vaccine Responses in Extremely Premature Infants Terminated NCT00138255
154 Prevalence and Clincial Spectrum of the 22q11 Deletion: A Population Based Study of Children and Congenital Heart Defects Terminated NCT00267397
155 Post-marketing Surveillance Study of GSK Biologicals' Live, Attenuated Measles, Mumps, Rubella and Varicella Vaccine, Priorix-Tetra, Following a Single Vaccine Dose Given According to Local Prescribing Information in the Philippines Withdrawn NCT01738841

Search NIH Clinical Center for Rubella

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Measles virus strain enders' attenuated edmonston live antigen
Mumps virus strain b level jeryl lynn live antigen
Rubella virus vaccine

Cochrane evidence based reviews: rubella

Genetic Tests for Rubella

Anatomical Context for Rubella

MalaCards organs/tissues related to Rubella:

41
Testes, Heart, Skin, Brain, Eye, T Cells, Liver

The Foundational Model of Anatomy Ontology organs/tissues related to Rubella:

19
Skin

Publications for Rubella

Articles related to Rubella:

(showing 12277, show less)
# Title Authors PMID Year
1
Genetic Characterization of Measles and Rubella Viruses Detected Through Global Measles and Rubella Elimination Surveillance, 2016-2018. 38 17
31269012 2019
2
Comparison of the LIAISON®XL and ARCHITECT IgG, IgM, and IgG avidity assays for the diagnosis of Toxoplasma, cytomegalovirus, and rubella virus infections. 38 17
30994178 2019
3
Battery Powered Portable Thermal Cycler for Continuous-Flow Polymerase Chain Reaction Diagnosis by Single Thermostatic Thermoelectric Cooler and Open-Loop Controller. 38 17
30987195 2019
4
Infectious antibodies in systemic lupus erythematosus patients. 9 38
19880558 2009
5
An interesting case of pachydermoperiostosis with idiopathic myelofibrosis associated with monosomy 22. 9 38
19659869 2009
6
Positive rates for rubella antibody in pregnant women and benefit of post-partum vaccination in a Japanese perinatal center. 9 38
18412777 2008
7
A case of common variable immunodeficiency syndrome associated with Takayasu arteritis. 9 38
17304891 2007
8
Collection tubes with or without gel separator did not interfere with detection of rubella virus antibodies IgM and IgG. 9 38
17847106 2007
9
Confirmed congenital rubella syndrome--A case report. 9 38
17111737 2006
10
Humoral immune response to primary rubella virus infection. 9 38
16522781 2006
11
Assessment of IgM enzyme immunoassay and IgG avidity assay for distinguishing between primary and secondary immune response to rubella vaccine. 9 38
16026863 2005
12
Detection of rubella immunoglobulin M from dried venous blood spots using a commercial enzyme immunoassay. 9 38
16168610 2005
13
Evaluation of diagnostic markers for measles virus infection in the context of an outbreak in Spain. 9 38
16207972 2005
14
Comparison of immulite with vidas for detection of infection in a low-prevalence population of pregnant women in The Netherlands. 9 38
11329456 2001
15
An immunoblot assay for detection of immunoglobulin M antibody to human herpesvirus 6. 9 38
10973462 2000
16
Decline of measles-specific immunoglobulin M antibodies after primary measles, mumps, and rubella vaccination. 9 38
9521134 1998
17
Viral arthritis. 9 38
9229181 1997
18
Enhanced spontaneous antibody response after coronary artery bypass surgery. 9 38
9187781 1997
19
Calreticulin binds hYRNA and the 52-kDa polypeptide component of the Ro/SS-A ribonucleoprotein autoantigen. 9 38
8666824 1996
20
Persistent rubella infection after erroneous vaccination in an immunocompromised patient with acute lymphoblastic leukemia in remission. 9 38
8636717 1995
21
The rubella virus RNA binding activity of human calreticulin is localized to the N-terminal domain. 9 38
7745733 1995
22
Identification of calreticulin as a rubella virus RNA binding protein. 9 38
7809119 1994
23
Differential antibody responses to rubella virus infection in males and females. 9 38
1431244 1992
24
Detection of rubella virus-specific immunoglobulin G (IgG), IgM, and IgA antibodies by immunoblot assays. 9 38
1572968 1992
25
Detection of rubella virus immunoglobulin G (IgG) and IgM antibodies in whole blood on Whatman paper: comparison with detection in sera. 9 38
1939573 1991
26
Evaluation of commercial enzyme linked immunosorbent assay for detection of B19 parvovirus IgM and IgG. 9 38
1660053 1991
27
Development of a highly specific and sensitive rubella immunoglobulin M antibody capture enzyme immunoassay that uses enzyme-labeled antigen. 9 38
2185260 1990
28
Rubella-specific IgM in reinfection and risk to the fetus. 9 38
2265806 1990
29
Rubella Immunity in Pregnant Iranian Women: A Systematic Review and Meta-Analysis. 38
31310069 2019
30
Rubella serosurvey and factors related to vaccine hesitancy in childbearing women in Italy. 38
31367512 2019
31
Quantification of neomycin in rubella vaccine by off/on metal ion mediated photoluminescence from functionalized graphene quantum dots. 38
31146209 2019
32
[Assessment of prenatal care for indigenous women in Brazil: findings from the First National Survey of Indigenous People's Health and Nutrition]. 38
31433037 2019
33
Retrospective evaluation of children with immune thrombocytopenic purpura and factors contributing to chronicity. 38
30470618 2019
34
Oral fluid: Non-invasive alternative for parvovirus B19 diagnosis? 38
31128380 2019
35
Need for heightening awareness of congenital rubella syndrome in the United States. 38
31379318 2019
36
Rubella seroprevalence and demographic feature analysis in pregnant women from Southern Pakistan. 38
31431775 2019
37
Teratogenic Rubella Virus Alters the Endodermal Differentiation Capacity of Human Induced Pluripotent Stem Cells. 38
31405163 2019
38
Retracing the molecular basis and evolutionary history of the loss of benzaldehyde emission in the genus Capsella. 38
31400223 2019
39
The 'Dangerous Cocktail': an epidemiological survey on the attitude of a population of pregnant women towards some pregnancy risk factors. 38
31373265 2019
40
Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms. 38
31430946 2019
41
Autism Narratives in Media Coverage of the MMR Vaccine-Autism Controversy under a Crip Futurism Framework. 38
29521536 2019
42
Vaccine hesitancy and (fake) news: Quasi-experimental evidence from Italy. 38
31429153 2019
43
First MRI With New Cochlear Implant With Rotatable Internal Magnet System and Proposal for Standardization of Reporting Magnet-Related Artifact Size. 38
31219967 2019
44
Safety and Seropositivity after Live Attenuated Vaccine in Adult Patients Receiving Hematopoietic Stem Cell Transplantation. 38
30959161 2019
45
Measles-Mumps-Rubella Vaccination in Children with Food Allergy. 38
31388919 2019
46
Acute idiopathic blind spot enlargement syndrome following measles, mumps and rubella vaccination. 38
31358170 2019
47
Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up. 38
31345639 2019
48
Measles, mumps, rubella (vaccine) and varicella vaccines in pediatric liver transplant: An initial analysis of post-transplant immunity. 38
31219224 2019
49
Field Test and Validation of the Multiplier Measles, Mumps, Rubella, and Varicella-Zoster Multiplexed Assay System in the Democratic Republic of the Congo by Using Dried Blood Spots. 38
31413172 2019
50
Calibration and Evaluation of Quantitative Antibody Titers for Varicella-Zoster Virus by Use of the BioPlex 2200. 38
31167847 2019
51
Vaccination Status in Pediatric Solid-Organ Transplant Recipients and Their Household Members. 38
31050613 2019
52
Preventing Measles among Immunosuppressed Cancer and Hematopoietic Cell Transplant Patients: A Position Statement by the American Society for Transplantation and Cellular Therapy. 38
31394271 2019
53
Immunisation of migrants in EU/EEA countries: Policies and practices. 38
31296374 2019
54
The risk of non-specific hospitalised infections following MMR vaccination given with and without inactivated vaccines in the second year of life. Comparative self-controlled case-series study in England. 38
31375437 2019
55
Trends in governmental expenditure on vaccination programmes in the Netherlands, a historical analysis. 38
31420172 2019
56
Identifying inequalities in childhood immunisation uptake and timeliness in southeast Scotland, 2008-2018: A retrospective cohort study. 38
31402236 2019
57
[Analysis on the characteristics of suspected vaccine-related deaths in Fujian Province, 2012-2017]. 38
31288344 2019
58
[A Case of Congenital Syphilis and Prozone Phenomenon]. 38
31414635 2019
59
Evaluation of the Abbott ARCHITECT™ cytomegalovirus IgM/IgG, rubella IgM/IgG, and syphilis treponemal antibodies enzyme immunoassays in a mother and child health center population. 38
30738692 2019
60
Comparison of two commercial ELISA kits for detection of rubella specific IgM in suspected congenital rubella syndrome cases and rubella IgG antibodies in a serosurvey of pregnant women. 38
30782464 2019
61
The association of ToRCH infection and congenital malformations: A prospective study in China. 38
31382146 2019
62
Overcoming the difficulty of achieving elimination status for measles and rubella due to imported infections: Estimation of the reproduction number R for measles and rubella. 38
31075426 2019
63
Implementation of the World's largest measles-rubella mass vaccination campaign in Bangladesh: a process evaluation. 38
31291922 2019
64
Rubella Resurgence in Japan 2018-2019. 38
31259366 2019
65
Cutaneous Granulomatous Disease With Presence of Rubella Virus in Lesions. 38
31166586 2019
66
Enhancing Preparedness against Rubella at the Workplace: Proactive Prevention Efforts by the Tokyo Metropolitan Government. 38
30918146 2019
67
Sero-epidemiological evaluation of rubella immunity among pre-marriage women in Iran. 38
30047822 2019
68
Congenital supravalvular and subvalvular pulmonary stenosis with hypoplastic pulmonary annulus associated with congenital rubella syndrome. 38
31296628 2019
69
Diabetic ketoacidosis in a child with congenital rubella syndrome: A case report and review of literature. 38
31405663 2019
70
Senile-Onset Subacute Sclerosing Panencephalitis, Presenting With Peculiar Findings. 38
30099908 2019
71
Cutaneous granulomas with primary immunodeficiency in children: a report of 17 new patients and a review of the literature. 38
30869812 2019
72
The immunomodulatory effects of measles-mumps-rubella vaccination on persistence of heterologous vaccine responses. 38
30791143 2019
73
Duration of immunity to measles, rubella and mumps during the first year of life. 38
31151799 2019
74
Hypersensitivity Reactions To Measles-Mumps-Rubella Vaccine In Patients With Ige-Mediated Cow's Milk Allergy. 38
31319219 2019
75
MMRdb: Measles, mumps, and rubella viruses database and analysis resource. 38
31352145 2019
76
A Systematic Review for Vaccine-Preventable Diseases on Ships: Evidence for Cross-Border Transmission and for Pre-Employment Immunization Need. 38
31366029 2019
77
Descriptive study of suspected congenital Zika syndrome cases during the 2015-2016 epidemic in Brazil. 38
31340371 2019
78
Identification of human parvovirus B19 among measles and rubella suspected patients from Cuba. 38
30817853 2019
79
Meningitis and epididymitis caused by Toscana virus infection imported to Switzerland diagnosed by metagenomic sequencing: a case report. 38
31286879 2019
80
Comparison of antibody response between boys and girls after infant and childhood vaccinations in the Netherlands. 38
31279563 2019
81
The Clinical Impact and Cost-effectiveness of Measles-Mumps-Rubella Vaccination to Prevent Measles Importations Among International Travelers From the United States. 38
30312374 2019
82
Characterisation of measles after the introduction of the combined measles-mumps-rubella (MMR) vaccine in 2004 with focus on the laboratory data, 2016 to 2019 outbreak, Romania. 38
31339098 2019
83
Sera from different age cohorts in Belgium show limited cross-neutralization between the mumps vaccine and outbreak strains. 38
30502489 2019
84
Assessment of Mumps Virus-Specific Antibodies: Comparison of Plaque Reduction Neutralization Test and Enzyme-Linked Immunosorbent Assay Estimates. 38
31299077 2019
85
National immunization strategies targeting migrants in six European countries. 38
29426661 2019
86
Increasing childhood vaccination coverage of the refugee and migrant population in Greece through the European programme PHILOS, April 2017 to April 2018. 38
31290391 2019
87
Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines. 38
31270247 2019
88
Reevaluating immunization delays after red blood cell transfusion. 38
31270825 2019
89
Coverage and outcomes of antenatal tests for infections: a population based survey in the Province of Trento, Italy. 38
29343192 2019
90
The indications and safety of polyvalent immunoglobulin for post-exposure prophylaxis of hepatitis A, rubella and measles. 38
31116633 2019
91
Assessment of Economic Burden of Concurrent Measles and Rubella Outbreaks, Romania, 2011-2012. 38
31107215 2019
92
Coverage survey of Measles-Rubella mass vaccination campaign in a rural area in Tamil Nadu. 38
31334150 2019
93
Simultaneous and rapid detection method for measles and rubella using single-tube multiplex real-time quantitative RT-PCR. 38
31253475 2019
94
Exploring childhood immunization among undocumented migrants in Sweden - following qualitative study and the World Health Organizations Guide to Tailoring Immunization Programmes (TIP). 38
31121558 2019
95
First report of the genomic characterization of rubella viruses circulating in Cameroon. 38
30822356 2019
96
Correction to Antifungal Phenylpropanoid Glycosides from Lippia rubella. 38
31181924 2019
97
Preclinical study of safety and immunogenicity of combined rubella and human papillomavirus vaccines: Towards enhancing vaccination uptake rates in developing countries. 38
31185296 2019
98
Risk Factors Associated With Accelerated Rubella IgG Antibody Loss in Previously Vaccinated, Treatment-Naive Patients With Juvenile Systemic Lupus Erythematosus: A Prospective Study. 38
30614217 2019
99
Clinical Manifestations, Prognosis, and Vaccination Status of Patients With Rubella Virus-Associated Uveitis. 38
30771336 2019
100
Congenital rubella syndrome at tertiary care hospital in North India: Results from a retrospective assessment. 38
31158287 2019
101
Laboratory-based investigation of fever with rash cases in the Maharashtra State - India, 2014 to 2017. 38
30680754 2019
102
Predictive Factors of Intraocular Pressure Level Evolution Over Time and Glaucoma Severity in Fuchs' Heterochromic Iridocyclitis. 38
31157832 2019
103
Serologic Status of Routine Childhood Vaccines, Cytomegalovirus, and Epstein-Barr Virus in Children With Inflammatory Bowel Disease. 38
30551205 2019
104
The fetal origins of mental illness. 38
31207234 2019
105
Trend in the rate of varicella and mumps vaccination in children under age three years in a tertiary children's hospital in Japan. 38
31211889 2019
106
Vaccine-preventable diseases and vaccination among Italian healthcare workers: a review of current literature. 38
31274016 2019
107
High level antibodies to TORCH in the IVIG preparation from Taiwanese. 38
31180949 2019
108
Modified measles with an atypical presentation 38
31203583 2019
109
Extragenital cutaneous warts - clinical presentation, diagnosis and treatment. 38
31241843 2019
110
Qualitative Assessment of Vaccine Hesitancy in Romania. 38
31213037 2019
111
The influence of neonatal Bacille Calmette-Guérin (BCG) immunisation on heterologous vaccine responses in infants. 38
31153688 2019
112
Travel medicine consultation: An opportunity to improve coverage for routine vaccinations. 38
30583868 2019
113
Genomic signature of early T-cell response is associated with lower antibody titer threshold for sterilizing immunity. 38
30940521 2019
114
Pediatricians' vaccine attitudes and practices before and after a major measles outbreak. 38
30009615 2019
115
Socioeconomic status differences in parental immunization attitudes and child immunization in Canada: Findings from the 2013 Childhood National Immunization Coverage Survey (CNICS). 38
30904601 2019
116
Is there any harm in administering extra-doses of vaccine to a person? Excess doses of vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2007-2017. 38
31155414 2019
117
Seroprevalence and durability of rubella virus antibodies in a highly immunized population. 38
31126859 2019
118
Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials. 38
31110098 2019
119
Diagnosis of congenital/perinatal infections by neonatologists: a national survey. 38
30914779 2019
120
Childhood infectious diseases and risk of non-Hodgkin's lymphoma according to the WHO classification: A reanalysis of the Italian multicenter case-control study. 38
31077355 2019
121
Seroprotection rates of vaccine-preventable diseases among newly arrived Eritrean asylum seekers in Switzerland: a cross-sectional study. 38
31094415 2019
122
Use of FTA Cards To Transport Throat Swabs and Oral Fluid Samples for Molecular Detection and Genotyping of Measles and Rubella Viruses. 38
30814262 2019
123
Progress Toward Measles Elimination - European Region, 2009-2018. 38
31048675 2019
124
Predicting congenital rubella syndrome in Japan, 2018-2019. 38
30807870 2019
125
Awareness and Factors Associated with Health Care Worker's Knowledge on Rubella Infection: A Study after the Introduction of Rubella Vaccine in Tanzania. 38
31091685 2019
126
Rubella Vaccination Coverage Among Women of Childbearing Age in Vietnam. 38
31100981 2019
127
Plasmonic gold chips for the diagnosis of Toxoplasma gondii, CMV, and rubella infections using saliva with serum detection precision. 38
30701339 2019
128
Maternal Viral Infection and Risk of Fetal Congenital Heart Diseases: A Meta-Analysis of Observational Studies. 38
30995883 2019
129
Seasonal influence on TORCH infection and analysis of multi-positive samples with indirect immunofluorescence assay. 38
30666721 2019
130
"Noninfectious" Cutaneous Granulomas in Primary Immunodeficiency Patients and Association With Rubella Virus Vaccine Strain. 38
31070095 2019
131
Antiviral immunity in chronic lymphocytic leukemia measured by anti-rubella antibody. 38
30659789 2019
132
Improving immunization strategies in patients with inflammatory bowel disease. 38
31040621 2019
133
Does Food Allergy Require Any Change in Measles-Mumps-Rubella Vaccination? 38
31104294 2019
134
Varicella zoster and fever rash surveillance in Lao People's Democratic Republic. 38
31068140 2019
135
Increase in Measles Cases - United States, January 1-April 26, 2019. 38
31048672 2019
136
A case of adult rubella in Japan. 38
30825652 2019
137
Measles in pregnancy. 38
31076492 2019
138
Applying sequential surveillance methods that use regression adjustment or weighting to control confounding in a multisite, rare-event, distributed setting: Part 2 in-depth example of a reanalysis of the measles-mumps-rubella-varicella combination vaccine and seizure risk. 38
31055178 2019
139
Controlling Measles through Politics and Policy. 38
31009080 2019
140
[Epidemiological characteristics of mumps in mainland China from 2004 to 2018 and key population for prevention and control]. 38
31104659 2019
141
Phylogeography of rubella virus in Asia: Vaccination and demography shape synchronous outbreaks. 38
31201039 2019
142
New vaccine introductions in Africa before and during the decade of vaccines - Are we making progress? 38
31076160 2019
143
Missed Opportunities for Rotavirus Vaccination. 38
31023829 2019
144
Organisation of preventive child health services: Key to socio-economic equity in vaccine uptake? 38
31096860 2019
145
Revaccination in Children Undergoing Autologous Hematopoietic Stem Cell Transplantation: Results of a Survey in Germany, Austria and Switzerland. 38
30602176 2019
146
Vaccination status of resident pediatricians and the potential risk for their patients - a cross-sectional questionnaire study in pediatric practices in Vienna. 38
31096960 2019
147
Epistaxis and gross haematuria with severe thrombocytopaenia associated with influenza vaccination. 38
31061198 2019
148
Will dual Japanese encephalitis and measles-rubella vaccination hinder measles and rubella eradication? 38
30833161 2019
149
Immunogenicity and safety of measles-rubella vaccine co-administered with attenuated Japanese encephalitis SA 14-14-2 vaccine in infants aged 8 months in China: a non-inferiority randomised controlled trial. 38
30833160 2019
150
[Elimination of measles in the WHO European Region-challenges persist]. 38
30887090 2019
151
Measles-Rubella Campaign: Could Things Have Been Done Differently? 38
31064912 2019
152
Long-term preservation of measles and rubella specific-IgG antibodies in children with enthesitis related arthritis on anti-TNFα treatment: a prospective controlled study. 38
31323665 2019
153
[National immunization program initiatives-What are their contribution to the elimination of measles and rubella in Germany?] 38
30788537 2019
154
[A study on measles and rubella antibody level in 319 pairs of mothers and infants in Songjiang District of Shanghai]. 38
30982273 2019
155
Measles and rubella serosurvey identifies rubella immunity gap in young adults of childbearing age in Zambia: The added value of nesting a serological survey within a post-campaign coverage evaluation survey. 38
30905529 2019
156
Highly affordable vaccines are critical for our continued efforts to reduce global childhood mortality. 38
30973039 2019
157
Transposable elements drive rapid phenotypic variation in Capsella rubella. 38
30877258 2019
158
Modelling a Supplementary Vaccination Program of Rubella Using the 2012⁻2013 Epidemic Data in Japan. 38
31027277 2019
159
Neuropathological Findings in a Case of IFIH1-Related Aicardi-Goutières Syndrome. 38
30952201 2019
160
Validation of monoplex assays detecting antibodies against Corynebacterium diphtheriae and Clostridium tetani toxins, rubella virus and parvovirus B19 for incorporation into Multiplex Serology. 38
30703462 2019
161
[Postvaccinal complications and management of suspected cases]. 38
30820614 2019
162
Goldenhar Syndrome: A Case Report. 38
31110581 2019
163
Child and adolescent health in northwestern Syria: findings from Healthy-Syria 2017 study. 38
31143699 2019
164
The MMR Vaccine and Autism. 38
30986133 2019
165
A step beyond the hygiene hypothesis-immune-mediated classes determined in a population-based study. 38
30961604 2019
166
Demystifying viral anterior uveitis: A review. 38
30345620 2019
167
Association of Ocular Inflammation and Rubella Virus Persistence. 38
30589932 2019
168
Rubella (German measles) revisited. 38
30967519 2019
169
Declining prevalence of pediatric sudden deafness during the past two decades. 38
30703660 2019
170
The comparative biochemistry of viruses and humans: an evolutionary path towards autoimmunity. 38
30504522 2019
171
Simultaneous circulation of arboviruses and other congenital infections in pregnant women in Rio de Janeiro, Brazil. 38
30685232 2019
172
A Third Dose of Measles-Mumps-Rubella Vaccine to Improve Immunity Against Mumps in Young Adults. 38
31112277 2019
173
Measles, mumps and rubella vs diphtheria-tetanus-acellular-pertussis-inactivated-polio-Haemophilus influenzae type b as the most recent vaccine and risk of early 'childhood asthma'. 38
31062020 2019
174
[Methodology of the 2nd seroprevalence study in Spain]. 38
31006772 2019
175
Parents' Experiences and Nurses' Perceptions of Decision-Making About Childhood Immunization. 38
31039630 2019
176
Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice. 38
31002409 2019
177
Intralesional immunotherapy for the treatment of warts: A network meta-analysis. 38
30003983 2019
178
Spatiotemporal distribution and determinants of measles incidence during a large outbreak, Italy, September 2016 to July 2018. 38
31039836 2019
179
Using protection motivation theory to predict intention to adhere to official MMR vaccination recommendations in Switzerland. 38
30581956 2019
180
Rate of Recurrence of Adverse Events Following Immunization: Results of 19 Years of Surveillance In Quebec, Canada. 38
30882727 2019
181
The use of normal human immunoglobulin (NHIG) for public health purposes in Queensland 2004-2014 and Australia 2014-2016 38
30879284 2019
182
A Phase II, Randomized, Double-blind, Controlled Safety and Immunogenicity Trial of Typhoid Conjugate Vaccine in Children Under 2 Years of Age in Ouagadougou, Burkina Faso: A Methods Paper. 38
30845330 2019
183
Research priorities for accelerating progress toward measles and rubella elimination identified by a cross-sectional web-based survey. 38
30898393 2019
184
Perception of rubella risk in pregnancy: an epidemiological survey on a sample of pregnant women. 38
30994165 2019
185
[Study of prevalence of protection against measles in health workers of Murcia Health Service]. 38
30833540 2019
186
Drivers and barriers for measles rubella vaccination campaign: A qualitative study. 38
31041218 2019
187
Accelerating measles and rubella elimination through research and innovation - Findings from the Measles & Rubella Initiative research prioritization process, 2016. 38
30904317 2019
188
Correlates of laboratory-confirmed measles in Japan, 2011-2015. 38
30803842 2019
189
The seroprevalence of Rubella in pregnant women in Turkey: a meta-analysis research of 90988 Rubella IgM, 84398 Rubella IgG, and 522 avidity results. 38
31019842 2019
190
Antifungal Phenylpropanoid Glycosides from Lippia rubella. 38
30817148 2019
191
Determination of rubella virus-specific humoral and cell-mediated immunity in pregnant women with negative or equivocal rubella-specific IgG in routine screening. 38
30711798 2019
192
Regulatory Diversification of INDEHISCENT in the Capsella Genus Directs Variation in Fruit Morphology. 38
30827915 2019
193
A case of immune-mediated type 1 diabetes mellitus due to congenital rubella ınfection. 38
30943684 2019
194
Measles, Mumps, Rubella Vaccination and Autism: A Nationwide Cohort Study. 38
30831578 2019
195
The rash with maculopapules and fever in adults. 38
30981291 2019
196
Immunogenicity and safety of the combined vaccine for measles, mumps, and rubella isolated or combined with the varicella component administered at 3-month intervals: randomised study. 38
30843921 2019
197
Rubella outbreak in the school children, Addis Ababa, Ethiopia: February-April 2018. 38
30885148 2019
198
Seroprevalence of measles, mumps & rubella antibodies among 5-10 years old children in north India. 38
31249206 2019
199
The rash with maculopapules and fever in children. 38
30981292 2019
200
Completeness and timeliness of diphtheria-tetanus-pertussis, measles-mumps-rubella, and polio vaccines in young children with chronic health conditions: A systematic review. 38
30814030 2019
201
Long-term protection against varicella with two-dose combination measles-mumps-rubella-varicella vaccine. 38
30765245 2019
202
Early disappearance of maternal anti-measles, mumps, rubella, and varicella antibodies in Indian infants. 38
30765170 2019
203
Multimodal safety assessment of measles-mumps-rubella vaccination after pediatric liver transplantation. 38
30171797 2019
204
Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study. 38
30849175 2019
205
Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial. 38
30765242 2019
206
Adult Vaccination Rates in the Mentally Ill Population: An Outpatient Improvement Project. 38
30866701 2019
207
Today's vaccination policies in Italy: The National Plan for Vaccine Prevention 2017-2019 and the Law 119/2017 on the mandatory vaccinations. 38
30994164 2019
208
Sample size calculation for estimating key epidemiological parameters using serological data and mathematical modelling. 38
30845904 2019
209
[Vaccination among healthcare workers in Italy: a narrative review]. 38
31377759 2019
210
Vaccine hesitancy: An overview on parents' opinions about vaccination and possible reasons of vaccine refusal. 38
30997357 2019
211
Social inequities in vaccination coverage among infants and pre-school children in Europe and Australia - a systematic review. 38
30866881 2019
212
Vaccination coverage in healthcare workers: a multicenter cross-sectional study in Italy. 38
31041405 2019
213
Acute depigmentation of the iris: a retrospective analysis of 22 cases. 38
30851772 2019
214
Measles and rubella seroimmunity in newly arrived adult immigrants in Sweden. 38
30676125 2019
215
Multiple-Point Evaluation Algorithms for Enhanced Precision of Pathogen-Specific Cerebrospinal Fluid/Serum Antibody Index Calculation. 38
29949398 2019
216
Myelinoclastic diffuse sclerosis (Schilder's disease) is immunologically distinct from multiple sclerosis: results from retrospective analysis of 92 lumbar punctures. 38
30819213 2019
217
A Measles Virus-Based Vaccine Candidate Mediates Protection against Zika Virus in an Allogeneic Mouse Pregnancy Model. 38
30429338 2019
218
Relevance or performance: potential savings associated with verification of prior results before performing microbiology analysis. 38
30293678 2019
219
50 Years Ago in The Journal of Pediatrics: Maternal and Congenital Rubella before 1964: Frequency, Clinical Features, and Search for Isoimmune Phenomena. 38
30684990 2019
220
Evaluation of the thermal stability of live-attenuated Rubella vaccine (Takahashi strain) formulated and lyophilized in different stabilizers. 38
30144493 2019
221
Intravitreal aflibercept for the treatment of choroidal neovascularization associated with rubella retinopathy. 38
29411259 2019
222
Health Departments' Experience With Mumps Outbreak Response and Use of a Third Dose of Measles, Mumps, and Rubella Vaccine. 38
30807465 2019
223
Successes and challenges for preventing measles, mumps and rubella by vaccination. 38
30852425 2019
224
CDC Guidance for Use of a Third Dose of MMR Vaccine During Mumps Outbreaks. 38
30789597 2019
225
A protracted mumps outbreak in Western Australia despite high vaccine coverage: a population-based surveillance study. 38
30558994 2019
226
What are the beliefs and perceptions of practice nurses' influence about the uptake of the measles, mumps, and rubella vaccine?: An integrative literature review. 38
30109727 2019
227
Low anti-rubella antibody levels in public facilities staff in Tokyo. 38
30723000 2019
228
Assessment of vaccination coverage of adolescents aged 16-18 years with an innovative electronic immunization record system. 38
30527973 2019
229
Austerity, measles and mandatory vaccination: cross-regional analysis of vaccination in Italy 2000-14. 38
30215716 2019
230
Timeliness and completeness of routine childhood vaccinations in young children residing in a district with recurrent vaccine-preventable disease outbreaks, Jerusalem, Israel. 38
30755293 2019
231
Chickenpox: An update. 38
29789159 2019
232
[Vaccination Controversies: An Adult Case of Post-Vaccinal Acute Disseminated Encephalomyelitis]. 38
30753808 2019
233
Identifying risk factors associated with acquiring measles in an outbreak among age-appropriately vaccinated school children: a cohort analysis. 38
29637399 2019
234
Implementing Universal Varicella Vaccination in Europe: The Path Forward. 38
30408002 2019
235
Timeliness of routine immunization in non-preterm children less than 2 years old using electronic data capture in an ambulatory setting in France in the context of vaccine hesitancy. 38
30638762 2019
236
Small head circumference at birth: an 8-year retrospective cohort study in China. 38
31263793 2019
237
School-based educational and on-site vaccination intervention among adolescents: study protocol of a cluster randomised controlled trial. 38
30700487 2019
238
An Intraocular Inflammatory Profile of Rubella Associated Uveitis. 38
29370571 2019
239
Polymerase Chain Reaction and Goldmann-Witmer Coefficient Testing in the Diagnosis of Infectious Uveitis in HIV-Positive and HIV-Negative Patients in South Africa. 38
29283745 2019
240
Severe Immune Thrombocytopenia Complicated by Intracerebral Haemorrhage Associated with Coronavirus Infection: A Case Report and Literature Review. 38
31410357 2019
241
Anti-Jo-1 Antibody-positive Interstitial Pneumonia in an Elderly Patient with Congenital Rubella Syndrome. 38
31308343 2019
242
The impact of Measles-Rubella vaccination on the morbidity and mortality from Congenital Rubella Syndrome in 92 countries. 38
30285537 2019
243
The value of tailoring vial sizes to populations and locations. 38
30578087 2019
244
Measles and rubella seroprevalence in a population of young adult blood donors, France 2013. 38
30869022 2019
245
Seroprevelence of rubella among children suspected of having measles in Gadarif Hospital, Eastern Sudan. 38
31384083 2019
246
Clinical manifestations of congenital rubella syndrome: A review of our experience in Vietnam. 38
30503658 2019
247
Decreased antibodies against rubella in previously vaccinated treatment-naïve childhood systemic lupus erythematous patients: a prospective case-control study. 38
29741129 2019
248
Outcomes for Nitazoxanide Treatment in a Case Series of Patients with Primary Immunodeficiencies and Rubella Virus-Associated Granuloma. 38
30680653 2019
249
Contrast-induced nephropathy in an animal model: Evaluation of novel biomarkers in blood and tissue samples. 38
31080747 2019
250
Last cases of rubella and congenital rubella syndrome in Spain, 1997-2016: The success of a vaccination program. 38
30454948 2019
251
Genetic characterisation of Measles virus variants identified during a large epidemic in Milan, Italy, March-December 2017. 38
30869017 2019
252
Aniridia: A Rare Manifestation Of Congenital Rubella Syndrome. 38
30868799 2019
253
Rubella Virus-Associated Cutaneous Granulomatous Disease: a Unique Complication in Immune-Deficient Patients, Not Limited to DNA Repair Disorders. 38
30607663 2019
254
Causal relationship between immunological responses and adverse reactions following vaccination. 38
30503656 2019
255
Vaccination Against Measles, Mumps, and Rubella in the Light of Current Epidemic Threats: Unjustified Postponement. 38
30758772 2019
256
Immunosuppression Does Not Affect Antibody Concentrations to Measles, Mumps, and Rubella in Patients with Inflammatory Bowel Disease. 38
30317494 2019
257
Congenital B-cell Acute Lymphoblastic Leukemia with Congenital Rubella Infection. 38
30806367 2019
258
Congenital and perinatal infections. 38
31324308 2019
259
Retrospective investigation of antibodies against chikungunya virus (CHIKV) in serum from febrile patients in Mozambique, 2009-2015: Implications for its prevention and control. 38
30897135 2019
260
The Association Between Documentation of Koplik Spots and Laboratory Diagnosis of Measles and Other Rash Diseases in a National Measles Surveillance Program in Japan. 38
30833942 2019
261
Clinical value of enzyme immunoassay that detects rubella-specific immunoglobulin M immediately after disease onset. 38
30549103 2019
262
Immunogenicity and safety of intramuscular versus subcutaneous administration of a combined measles, mumps, rubella, and varicella vaccine to children 12 to 18 months of age. 38
30481110 2019
263
Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial. 38
30724658 2019
264
The Efficacy and Safety of Intralesional Immunotherapy with Measles, Mumps, Rubella Virus Vaccine for the Treatment of Common Warts in Adults. 38
30775294 2019
265
Measles, mumps, and rubella: A cross-sectional study of susceptibility to vaccine-preventable diseases among young people in India. 38
30705481 2019
266
Intralesional Injection of the Measles-Mumps-Rubella Vaccine into Resistant Palmoplantar Warts: A Randomized Controlled Trial. 38
30666071 2019
267
Relationship Between Media Coverage and Measles-Mumps-Rubella (MMR) Vaccination Uptake in Denmark: Retrospective Study. 38
30672743 2019
268
Revaccination With Measles-Mumps-Rubella Vaccine and Infectious Disease Morbidity: A Danish Register-based Cohort Study. 38
29846533 2019
269
Pre-vaccination IgG screening for mumps is the most cost-effectiveness immunization strategy among Health Care Workers. 38
30779686 2019
270
A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration. 38
30785357 2019
271
"Get the shot, now!" Disentangling content-related and social cues in physician-patient communication. 38
30886727 2019
272
Adverse pregnancy outcomes among pregnant women with acute Rubella infections in Mwanza city, Tanzania. 38
30391418 2019
273
The risk factors of exposure to rubella among pregnant women in Zaria 2013. 38
30949283 2019
274
Erratum: Diagnosis of rubella virus using antigen-conjugated Au@Pt nanorods as nanozyme probe [Corrigendum]. 38
30863060 2019
275
Sero-epidemiological study in prediction of the risk groups for measles outbreaks in Vojvodina, Serbia. 38
31071124 2019
276
Influence of non-homogeneous mixing on final epidemic size in a meta-population model. 38
29909739 2019
277
Breastfeeding Prevalence at Time of Vaccination: Results of a Pilot Study in 6 Italian Regions. 38
30657734 2019
278
Mandatory vaccination of infants in France: Is that the way forward? 38
30672344 2019
279
Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders. 38
30478005 2019
280
Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies. 38
30463418 2019
281
Vaccination strategy for epidemic viral diseases in healthcare workers: Cut-off for optimal immunization. 38
30064948 2019
282
Isolated fetal echogenic bowel in a retrospective cohort: The role of infection screening. 38
30388607 2018
283
Spontaneous Lens Absorption Initially Misdiagnosed as Crystalline Lens Luxation 38
30605941 2018
284
Integrating Blood Collection within Household Surveys: Lessons Learned from Nesting a Measles and Rubella Serological Survey within a Post-Campaign Coverage Evaluation Survey in Southern Province, Zambia. 38
30277204 2018
285
A Prospective OCT Study of Rubella Retinopathy. 38
31047196 2018
286
No. 368-RUBELLA IN PREGNANCY. 38
30527073 2018
287
Talk to Patients About: Rubella. 38
30605557 2018
288
Sero-prevalence of rubella among pregnant women in India, 2017. 38
30448333 2018
289
Microsynteny analysis to understand evolution and impact of polyploidization on MIR319 family within Brassicaceae. 38
30242472 2018
290
The Role of Laboratory Medicine for Health During Pregnancy. 38
30574038 2018
291
Dominant SCN2A Mutation Causes Familial Episodic Ataxia and Impairment of Speech Development. 38
30165711 2018
292
Local and distal involution of recalcitrant warts after a single intralesional dose of measles, mumps, and rubella vaccine. 38
30677806 2018
293
Comparison of three immunoassays for determination of immunity to rubella virus in healthcare workers. 38
30237054 2018
294
Development of Indirect Immunofluorescence Technique for the Identification of MRC5 Working Seed Cell. 38
30256037 2018
295
The frequency of allergic reactions to the triple viral vaccine in 94 patients with egg allergy 38
30653865 2018
296
[Surveillance data on notifiable infectious diseases among students aged 6-22 years in China, 2011-2016]. 38
30572383 2018
297
Immunisation rates among children in Nuuk. 38
29392992 2018
298
Post-exposure prophylaxis for measles with immunoglobulins revised recommendations of the standing committee on vaccination in Germany. 38
30478003 2018
299
Constrained minimization problems for the reproduction number in meta-population models. 38
29445854 2018
300
Descriptive Study of Rubella Titer Status in Infertility Patients. 38
30742748 2018
301
Communicable Diseases in the Mediterranean Region. 38
30479598 2018
302
Global Routine Vaccination Coverage - 2017. 38
30439873 2018
303
Epidemiology of rubella infection and genotyping of rubella virus in Cote d'Ivoire, 2012-2016. 38
29984523 2018
304
Measles and Rubella Seroprevalence in Mother-Infant Pairs in Rural Nepal and the United States: Pre- and Post-Elimination Populations. 38
30403166 2018
305
Global landscape of measles and rubella surveillance. 38
30318167 2018
306
Rubella virus infections and immune status among pregnant women before the introduction of rubella vaccine in Amhara Regional State, Ethiopia. 38
30165188 2018
307
Preventing vertical virus infections: the role of serologic screening of pregnant women. 38
29971491 2018
308
Common findings on head computed tomography in neonates with confirmed congenital Zika syndrome. 38
30559553 2018
309
Systemic Associations of Childhood Glaucoma: A Review. 38
30452766 2018
310
Artificial Intelligence Based Skin Classification Using GMM. 38
30460413 2018
311
Community-acquired acute meningitis and encephalitis: a narrative review. 38
30309300 2018
312
Prevention of Infectious Diseases due to Immunosuppression and Vaccinations in Asian Patients with Inflammatory Bowel Disease. 38
30505836 2018
313
Perspectives on the Measles, Mumps and Rubella Vaccination among Somali Mothers in Stockholm. 38
30388799 2018
314
Mumps epidemiology in Cuba between 2004 and 2015. 38
30078131 2018
315
A randomized, blinded, placebo-controlled trial comparing antibody responses to homeopathic and conventional vaccines in university students. 38
30352746 2018
316
Correlation Analysis of Rubella Incidence and Meteorological Variables Based on Chinese Medicine Theory of Yunqi. 38
30467697 2018
317
Long-term monitoring of virus antibody titers in human intravenous immunoglobulin lots derived from donors in Japan. 38
30284288 2018
318
The development of a bead-based multiplex immunoassay for the detection of IgG antibodies to CMV and EBV. 38
30056034 2018
319
Prior abortion history and pregnancy hypertensive disorders in primiparous gravidae. 38
30527107 2018
320
A process evaluation of how the routine vaccination programme is implemented at GP practices in England. 38
30348182 2018
321
Seroprevalance of Rubella in an Urban Infertility Clinic - Observations and Challenges Ahead. 38
30787525 2018
322
Copper Supplementation in Premature Infants With Parenteral Nutrition-Associated Cholestasis. 38
29529337 2018
323
Immunisation status of children with cerebral palsy in rural Bangladesh: results from the Bangladesh Cerebral Palsy Register (BCPR). 38
30360749 2018
324
Measles-Rubella vaccination campaign: A trust deficit? 38
30306966 2018
325
Into Darkness and Silence: What Caused Helen Keller's Deafblindness? 38
29741601 2018
326
Social capital, trust in health information, and acceptance of Measles-Rubella vaccination campaign in Tamil Nadu: A case-control study. 38
29943738 2018
327
Vaccination Status and Antibody Titers against Rubella and Measles among Japanese Female College Students Majoring in Childcare between 2015 and 2018. 38
30282845 2018
328
Acute Encephalitis with Atypical Presentation of Rubella in Family Cluster, India. 38
30226166 2018
329
Passive Micropump for Highly Stable, Long-Termed, and Large Volume of Droplet Generation/Transport Inside 3D Microchannels Capable of Surfactant-Free and Droplet-Based Thermocycled Reverse Transcription-Polymerase Chain Reactions Based on a Single Thermostatic Heater. 38
30215252 2018
330
Rubella Virus Strain-Associated Differences in the Induction of Oxidative Stress Are Independent of Their Interferon Activation. 38
30282907 2018
331
Burden of Congenital Rubella Syndrome (CRS) in Bangladesh: Systematic review of existing literature and transmission modelling of sero-prevalence studies. 38
30289078 2018
332
The Prevalence of Anti-Rubella Antibodies in Pregnant Women of Turkey, Results of 94508 Patients in a Tertiary Referral Center. 38
30381819 2018
333
G1m1 predominance of intrathecal virus-specific antibodies in multiple sclerosis. 38
30349866 2018
334
Clinical epidemiology of congenital heart disease in Nigerian children, 2012-2017. 38
30230273 2018
335
Mumps Outbreak in a Marshallese Community - Denver Metropolitan Area, Colorado, 2016-2017. 38
30335736 2018
336
Cost of Public Health Response and Outbreak Control With a Third Dose of Measles-Mumps-Rubella Vaccine During a University Mumps Outbreak-Iowa, 2015-2016. 38
30302350 2018
337
Humoral immune response of childhood acute lymphoblastic leukemia survivors against the measles, mumps, and rubella vaccination. 38
29614919 2018
338
Improving measles incidence inference using age-structured serological data. 38
30078387 2018
339
Measles Outbreak in a Highly Vaccinated Population - Israel, July-August 2017. 38
30359348 2018
340
[Non-specific effects of vaccination in Denmark]. 38
30375964 2018
341
To the editor: Response to Willame, et al., published in Vaccine 35 (2017) 5551-5558, entitled "Pain caused by measles, mumps, and rubella vaccines: A systematic literature review". 38
30348361 2018
342
Reply to Lee et al.'s letter to the editor pertaining to our publication entitled "Pain caused by measles, mumps, and rubella vaccines: A systematic literature review". 38
30348362 2018
343
Vaccine Rubella: A Rare Cause of Post-transplant Hematopoietic Death, but a Major Public Health Problem. 38
30349846 2018
344
Notes from the Field: Rubella Infection in an Unvaccinated Pregnant Woman - Johnson County, Kansas, December 2017. 38
30307903 2018
345
The Relationship between Anti-Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and the Rubella Virus. 38
30284774 2018
346
Vaccination Coverage for Selected Vaccines and Exemption Rates Among Children in Kindergarten - United States, 2017-18 School Year. 38
30307904 2018
347
Hong Kong Institute of Allergy and Hong Kong Society for Paediatric Immunology Allergy & Infectious Diseases joint consensus statement 2018 on vaccination in egg-allergic patients. 38
30318478 2018
348
Vaccination Coverage Among Children Aged 19-35 Months - United States, 2017. 38
30307907 2018
349
Emerging Topics in Vaccine Therapeutics for Adolescents and Adults: An Update for Immunizing Pharmacists. 38
30352534 2018
350
Investigation of an increase in large local reactions following vaccine schedule change to include DTaP-HB-IPV-Hib (Infanrix-hexa®) and MMRV (ProQuad®) at 18 months of age. 38
30269915 2018
351
Divergent approaches in the vaccination of recently arrived migrants to Europe: a survey of national experts from 32 countries, 2017. 38
30326996 2018
352
'Hesitant compliers': Qualitative analysis of concerned fully-vaccinating parents. 38
29031695 2018
353
Congenital Viral Infection: Traversing the Uterine-Placental Interface. 38
30048217 2018
354
Development and application of a multiplex assay for the simultaneous measurement of antibody responses elicited by common childhood vaccines. 38
30087048 2018
355
Dual-chamber injection device for measles-rubella vaccine: The potential impact of introducing varying sizes of the devices in 3 countries. 38
30146404 2018
356
Sentinel Surveillance for Congenital Rubella Syndrome - India, 2016-2017. 38
30212443 2018
357
Congenital rubella syndrome surveillance in South Africa using a sentinel site approach: a cross-sectional study. 38
30203002 2018
358
Strengthening routine immunization through measles-rubella elimination. 38
30041881 2018
359
Multimodal imaging in serologically confirmed Rubella retinopathy. 38
29934649 2018
360
Impact of Maternal BMI on Rubella Nonimmunity at Antenatal Screening. 38
30120821 2018
361
High BMI: A New Determinant of Impaired Rubella Immunity During Pregnancy? 38
30226004 2018
362
Rubella Viruses Shift Cellular Bioenergetics to a More Oxidative and Glycolytic Phenotype with a Strain-Specific Requirement for Glutamine. 38
29950419 2018
363
Alterations in Cell Mechanics by Actin Cytoskeletal Changes Correlate with Strain-Specific Rubella Virus Phenotypes for Cell Migration and Induction of Apoptosis. 38
30217036 2018
364
Childhood infectious diseases and risk of multiple myeloma: an analysis of the Italian multicentre case-control study. 38
29843844 2018
365
Diagnosis and outcomes of pregnant women with Zika virus infection in two municipalities of Risaralda, Colombia: Second report of the ZIKERNCOL study. 38
29894797 2018
366
Sudden Sensorineural Hearing Loss in Children: A Report of 75 Cases. 38
30063499 2018
367
Population Size Dependency of Measles Epidemic That Was Scalable from Japanese Prefectures to European Countries. 38
29709991 2018
368
Prevalence of Inadequate Immunity to Measles, Mumps, Rubella, and Varicella in MLB and NBA Athletes. 38
29792776 2018
369
Development and Use of an Endpoint Titration Assay To Characterize Mumps IgG Avidity following Measles, Mumps, and Rubella Vaccination and Wild-Type Mumps Infection. 38
30209129 2018
370
Large outbreak of mumps virus genotype G among vaccinated students in Norway, 2015 to 2016. 38
30255834 2018
371
Characteristics of Large Mumps Outbreaks in the United States during July 2010-December 2015. 38
30204850 2018
372
Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial. 38
30104117 2018
373
Active immunization status against measles, mumps, rubella, hepatitis B in internationally adopted children, surveyed at the university hospital of Palermo, Sicily. 38
30062371 2018
374
Seroprevalence and Determinants Associated with Mumps Antibodies after 20 Years of MMR Vaccination in Urban Area of Shanghai, China. 38
30249033 2018
375
Rubella virus neutralizing antibody response after a third dose of measles-mumps-rubella vaccine in young adults. 38
30107992 2018
376
Pediatric Wells syndrome (eosinophilic cellulitis) after vaccination: A case report and review of the literature. 38
29998475 2018
377
Impact of history of febrile convulsions on the risk difference of febrile convulsions with the tetravalent measles-mumps-rubella-varicella vaccine: Post-hoc exploratory analysis of results from a matched-cohort study. 38
30131195 2018
378
Post-immunisation fever and the antibody response to measles-containing vaccines. 38
29886856 2018
379
[Quantifying the impact of mass vaccination programmes on notified cases in the Netherlands]. 38
30306758 2018
380
Rubella Virus Genotype 1E in Travelers Returning to Japan from Indonesia, 2017. 38
30124420 2018
381
Evaluating Variability in Immunization Requirements and Policy Among U.S. Colleges and Universities. 38
30236997 2018
382
Identification of determinants associated with uptake of the first dose of the human papillomavirus vaccine in Denmark. 38
30111513 2018
383
Rate of Recurrence of Adverse Events Following Immunization: Results of 19 Years of Surveillance Ii Quebec, Canada. 38
30204662 2018
384
Updated NACI recommendations for measles post-exposure prophylaxis. 38
31015814 2018
385
Detection of bovine viral diarrhoea virus nucleic acid, but not infectious virus, in bovine serum used for human vaccine manufacture. 38
29941334 2018
386
Adherence and immune response to revaccination following hematopoietic stem cell transplantation at a pediatric onco-hematology reference center. 38
29668078 2018
387
Heterogeneity and longevity of antibody memory to viruses and vaccines. 38
30096134 2018
388
Delivery of Multiple Child and Maternal Health Interventions during Supplementary Immunization Campaign in Rwanda, 2013: Lessons Learnt. 38
30882095 2018
389
Effect of early natal supplementation of paracetamol on attenuation of exotoxin/endotoxin induced pyrexia and precipitation of autistic like features in albino rats. 38
29327281 2018
390
Persistent detection of Zika virus RNA from an infant with severe microcephaly - a case report. 38
30097025 2018
391
Performance of National Measles Case-Based Surveillance Systems in The WHO African Region. 2012 - 2016. 38
30957101 2018
392
Progress and challenges in measles and rubella elimination in the WHO European Region. 38
28651838 2018
393
The intrathecal polyspecific antiviral immune response (MRZ reaction): A potential cerebrospinal fluid marker for multiple sclerosis diagnosis. 38
29957390 2018
394
No. 203-Rubella in Pregnancy. 38
30103885 2018
395
Epidemiological changes in rubella IgG antibody levels detected in antenatal women from a retrospective rubella seroprevalence study. 38
29209940 2018
396
Live rubella vectors can express native HIV envelope glycoproteins targeted by broadly neutralizing antibodies and prime the immune response to an envelope protein boost. 38
30037665 2018
397
Suppression of Melatonin Secretion in Totally Visually Blind People by Ocular Exposure to White Light: Clinical Characteristics. 38
29625838 2018
398
Exhaustive TORCH Pathogen Diagnostics Corroborate Zika Virus Etiology of Congenital Malformations in Northeastern Brazil. 38
30089647 2018
399
Congenital Rubella Syndrome in The African Region - Data from Sentinel Surveillance. 38
30957103 2018
400
MMR and MMRV vaccines. 38
28757060 2018
401
A double-blind, randomized, controlled, multi-center safety and immunogenicity study of a refrigerator-stable formulation of VARIVAX®. 38
30146405 2018
402
Seroprevalence of Maternal and Cord Antibodies Specific for Diphtheria, Tetanus, Pertussis, Measles, Mumps and Rubella in Shunyi, Beijing. 38
30158679 2018
403
Should Mumps Be Higher Up on the Public Health Agenda in India? A Concern for Global Health Security. 38
30087277 2018
404
Seroprevalence of Zika virus and Rubella virus IgG among blood donors in Rwanda and in Sweden. 38
29663453 2018
405
Vaccination in newly arrived immigrants to the European Union. 38
28602605 2018
406
A report on the status of vaccination in Europe. 38
30037416 2018
407
National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2017. 38
30138305 2018
408
How are children who are delayed in the Childhood Vaccination Programme vaccinated: A nationwide register-based cohort study of Danish children aged 15-24 months and semi-structured interviews with vaccination providers. 38
30024308 2018
409
Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines. 38
30053915 2018
410
The optimal dose of disease-specific antibodies for post-exposure prophylaxis of measles and rubella in Australia: new guidelines recommended. 38
29865869 2018
411
Status of Measles Elimination in Eleven Countries with High Routine Immunisation Coverage in The WHO African Region. 38
30766973 2018
412
Benefits and Challenges in Using Seroprevalence Data to Inform Models for Measles and Rubella Elimination. 38
29562334 2018
413
Measles-Rubella Supplementary Immunization Activity Readiness Assessment - India, 2017-2018. 38
29975677 2018
414
Line Immunoassay: A Rapid Test for Screening TORCH Complex in Antenatal Patients with Bad Obstetric History. 38
30141457 2018
415
Towards rubella elimination in Japan. 38
29976516 2018
416
The Impact of Recent Rubella Vaccine Introduction in 5 Countries in The African Region. 38
30957104 2018
417
[Seroprevalence of anti-rubella and anti-cytomegalovirus IgG antibodies in women aged between 16 and 40 years, living in Tunja, Colombia]. 38
30843984 2018
418
Sequence and functional characterization of MIRNA164 promoters from Brassica shows copy number dependent regulatory diversification among homeologs. 38
29532337 2018
419
Information, education, and health behaviors: Evidence from the MMR vaccine autism controversy. 38
29717799 2018
420
Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. 38
29426830 2018
421
Surveillance of microcephaly and selected brain anomalies in Argentina: Relationship with Zika virus and other congenital infections. 38
29921033 2018
422
Newborn Glaucoma: Do not Forget Infections. 38
29847359 2018
423
Fetal Anemia Causing Hydrops Fetalis From an Alpha-Globin Variant: Homozygous Hemoglobin Constant Spring. 38
29240037 2018
424
Recurrent invasive group A streptococcal infection with four-limb amputation in an immunocompetent child. 38
30061131 2018
425
Mumps Outbreaks at Four Universities - Indiana, 2016. 38
30048422 2018
426
[Prevalence of maternal measles, rubella, mumps and varicella antibodies in the first six months of life]. 38
30156519 2018
427
Measles, mumps, and rubella vaccine in genital warts: A case report of two patients. 38
30623187 2018
428
Mumps in the Vaccination Age: Global Epidemiology and the Situation in Germany. 38
30065192 2018
429
The evolution of vaccines for early childhood: the MMRV. 38
30062378 2018
430
In Search of Factors Negatively Affecting Vaccine Immunity to Pertussis in Preschool Children Before the Administration of the First Booster. 38
29986481 2018
431
Persistence of Vaccine-Induced Immunity in Preschool Children: Effect of Gestational Age. 38
30033997 2018
432
Prevalence and risk factors of measles seronegativity in a cohort of HIV-positive subjects: a retrospective study. 38
29573535 2018
433
High-Density Redox Amplified Coulostatic Discharge-Based Biosensor Array. 38
30559530 2018
434
The Anti-vaccination Movement: A Regression in Modern Medicine. 38
30186724 2018
435
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents). 38
29459143 2018
436
A Microneedle Patch for Measles and Rubella Vaccination Is Immunogenic and Protective in Infant Rhesus Macaques. 38
29701813 2018
437
Seroprevalence of antibodies to measles and rubella eight months after a vaccination campaign in the southeast of Iran. 38
29420120 2018
438
Paternally expressed imprinted genes associate with hybridization barriers in Capsella. 38
29808019 2018
439
Bilateral Deafness as a Complication of the Vaccination-A Case Report. 38
29993212 2018
440
Immunological Characteristics of Schizophrenia. 38
29864757 2018
441
ICTV Virus Taxonomy Profile: Togaviridae. 38
29745869 2018
442
Progress Toward Rubella and Congenital Rubella Syndrome Control - South-East Asia Region, 2000-2016. 38
29851943 2018
443
Adverse Events Following Immunization in Brazil: Age of Child and Vaccine-Associated Risk Analysis Using Logistic Regression. 38
29865181 2018
444
Mandatory vaccinations in European countries, undocumented information, false news and the impact on vaccination uptake: the position of the Italian pediatric society. 38
29898770 2018
445
Resurgence risk for measles, mumps and rubella in France in 2018 and 2020. 38
29945697 2018
446
Assessment of mumps-containing vaccine effectiveness during an outbreak: Importance to introduce the 2-dose schedule for China. 38
29377772 2018
447
Parallel Evolution of Common Allelic Variants Confers Flowering Diversity in Capsella rubella. 38
29764984 2018
448
Vaccines and the risk of acute disseminated encephalomyelitis. 38
29784468 2018
449
Vaccine-preventable diseases, vaccines and Guillain-Barre' syndrome. 38
29880241 2018
450
Sociodemographic predictors are associated with compliance to a vaccination-reminder in 9692 girls age 14, Denmark 2014-2015. 38
29868358 2018
451
Measles high school vaccination program, 2014-2015: online survey of parents in NSW, Australia. 38
29925088 2018
452
Can Flanders resist the measles outbreak? Assessing vaccination coverage in different age groups among Flemish residents. 38
29716667 2018
453
A Bayesian space-time model for clustering areal units based on their disease trends. 38
29917057 2018
454
Immunization in end stage renal disease: The perception of waiting list patients. 38
29337400 2018
455
Immunization Mandates, Vaccination Coverage, and Exemption Rates in the United States. 38
29977973 2018
456
Vaccination status and needs of asylum-seeking children in Denmark: a retrospective data analysis. 38
29653865 2018
457
The MRZ reaction and a quantitative intrathecal IgG synthesis may be helpful to differentiate between primary central nervous system lymphoma and multiple sclerosis. 38
29511863 2018
458
Geographic Spread of Influenza under the Influence of Community Population Size, Which Differed from That of Measles and Rubella. 38
29491244 2018
459
Rubella infection in pregnancy and congenital rubella in United Kingdom, 2003 to 2016. 38
29766840 2018
460
Safety, tolerability and immunogenicity of intramuscular administration of PRP-CRM197 Hib vaccine to healthy Japanese children: An open-label trial. 38
29685594 2018
461
Standardization of rubella immunoassays. 38
29486385 2018
462
Australian rubella serosurvey 2012-2013: On track for elimination? 38
29661586 2018
463
Competitive ability of Capsella species with different mating systems and ploidy levels. 38
29471370 2018
464
Seroprevalence of HIV, HTLV, CMV, HBV and rubella virus infections in pregnant adolescents who received care in the city of Belém, Pará, Northern Brazil. 38
29769062 2018
465
Two Imported Cases of Congenital Rubella Syndrome and Infection-Control Challenges in New York State, 2013-2015. 38
28510706 2018
466
How Do We Approach Anti-Vaccination Attitudes? 38
30228713 2018
467
Waning immunity of one-dose measles-mumps-rubella vaccine to mumps in children from kindergarten to early school age: a prospective study. 38
29478347 2018
468
Therapeutic Outcome of Intralesional Immunotherapy in Cutaneous Warts Using the Mumps, Measles, and Rubella Vaccine: A Randomized, Placebo-controlled Trial. 38
29785233 2018
469
Diagnostic Yield of Laboratory Methods and Value of Viral Genotyping during an Outbreak of Mumps in a Partially Vaccinated Population in British Columbia, Canada. 38
29491021 2018
470
Prospective Study of Live Attenuated Vaccines for Patients with Nephrotic Syndrome Receiving Immunosuppressive Agents. 38
29499990 2018
471
Introduction of new and reinforcement of existing compulsory vaccinations in Italy: first evaluation of the impact on vaccination coverage in 2017. 38
29871721 2018
472
Update From the Advisory Committee on Immunization Practices. 38
29741721 2018
473
Vaccination Coverage Among Children Aged 2 Years - U.S. Affiliated Pacific Islands, April-October, 2016. 38
29795077 2018
474
Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study. 38
29337653 2018
475
Vaccination Status and Other Preventive Measures in Medical Schools. Big Needs and Opportunities. 38
30195701 2018
476
Frequent Community Use of Antibiotics among a Low-Economic Status Population in Manila, the Philippines: A Prospective Assessment Using a Urine Antibiotic Bioassay. 38
29512485 2018
477
Immunization Offer Targeting Migrants: Policies and Practices in Italy. 38
29757209 2018
478
Management and control of communicable diseases in schools and other child care settings: systematic review on the incubation period and period of infectiousness. 38
29716545 2018
479
Long-term Seroprotection Rates Following Second Dose of Measles as MMR Vaccine at 15 months in Indian Children. 38
29428921 2018
480
Association between false-positive TORCH and antiphospholipid antibodies in healthy pregnant women. 38
29157179 2018
481
TORCH (toxoplasmosis, rubella, cytomegalovirus, and herpes simplex virus) screening of small for gestational age and intrauterine growth restricted neonates: efficacy study in a single institute in Korea. 38
29713357 2018
482
Immunity After Childhood Vaccinations in Perinatally HIV-exposed Children With and Without HIV Infection in Latin America. 38
29140938 2018
483
Sonographic Diagnosis of Meningoencephalitis in Newborns and Infants. 38
29534259 2018
484
Epidemiological profile and progress toward rubella elimination in China. 10 years after nationwide introduction of rubella vaccine. 38
29550193 2018
485
Impact of Vaccination History on Serological Testing in Pregnant Women. 38
29276161 2018
486
Evaluation of measles and rubella integrated surveillance system in Apulia region, Italy, 3 years after its introduction. 38
29532766 2018
487
A digital microfluidic system for serological immunoassays in remote settings. 38
29695457 2018
488
Imported Congenital Rubella Syndrome, United States, 2017. 38
29553333 2018
489
A new species of Polietina (Diptera: Muscidae) from South America, with an updated phylogeny of the genus and a review of species' identity in GenBank. 38
29690186 2018
490
Unintended consequences and the paradox of control: Management of emerging pathogens with age-specific virulence. 38
29630603 2018
491
Zika virus: a public health perspective. 38
29406461 2018
492
Recognizing Measles, Mumps, and Rubella in the Emergency Department. 38
29715253 2018
493
Management of newly diagnosed high-risk and intermediate-risk follicular lymphoma with 90 Y ibritumomab tiuxetan in a phase II study. 38
29709062 2018
494
Quantifying the impact of mass vaccination programmes on notified cases in the Netherlands. 38
29534768 2018
495
Epidemiology of vaccine-preventable diseases in Japan: considerations for pre-travel advice for the 2019 Rugby World Cup and 2020 Summer Olympic and Paralympic Games. 38
30057855 2018
496
[Parotiditis in Chile: clinical and molecular characterization of two cases in a highly vaccinated population]. 38
29912260 2018
497
A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK. 38
29576304 2018
498
Voluntary termination of pregnancy: An opportunity for Measles, Mumps and Rubella vaccination in an Italian healthcare local unit. 38
29261361 2018
499
Rubella antibodies in cord blood sera in Portugal: association with maternal age and vaccination status. 38
29458448 2018
500
Imported case of measles in a university setting leading to an outbreak of measles in Edinburgh, Scotland from September to December 2016. 38
29564994 2018
501
Methods for addressing "innocent bystanders" when evaluating safety of concomitant vaccines. 38
29441647 2018
502
How often do children receive their vaccinations late, and why? 38
29619485 2018
503
Extension of French vaccination mandates: from the recommendation of the Steering Committee of the Citizen Consultation on Vaccination to the law. 38
29717696 2018
504
Safety and Immunogenicity of the HPV-16/18 AS04-adjuvanted Vaccine in 4-6-year-old Girls: Results to Month 12 From a Randomized Trial. 38
29424799 2018
505
Impact of a vaccination programme in children vaccinated with ProQuad, and ProQuad-specific effectiveness against varicella in the Veneto region of Italy. 38
29506477 2018
506
Monoclonal immunoglobulin heavy chain gene rearrangement in Fuchs' uveitis. 38
29523105 2018
507
Seroprevalence of antibodies against varicella zoster virus and rubella virus among newly recruited expatriate healthcare workers: a cross-sectional study. 38
29567844 2018
508
Health risks and precautions for visitors to the Tokyo 2020 Olympic and Paralympic Games. 38
29360525 2018
509
Rubella seroprevalence among pregnant women in Beijing, China. 38
29544450 2018
510
Congenital microcephaly in Quebec: baseline prevalence, risk factors and outcomes in a large cohort of neonates. 38
28676560 2018
511
Higher Rates of Protein Evolution in the Self-Fertilizing Plant Arabidopsis thaliana than in the Out-Crossers Arabidopsis lyrata and Arabidopsis halleri. 38
29608724 2018
512
Assessing the Effectiveness and Cost-Benefit of Test-and-Vaccinate Policy for Supplementary Vaccination against Rubella with Limited Doses. 38
29565821 2018
513
Large choroidal excavation in a patient with rubella retinopathy. 38
29077180 2018
514
False-Positive Monospot in a Returning Traveler with Dengue Fever. 38
29514339 2018
515
Pediatric Cataract - Importance of Early Detection and Management. 38
29119464 2018
516
Assessment of Humoral Immunity to Hepatitis B, Measles, Rubella, and Mumps in Children After Chemotherapy. 38
29309372 2018
517
Association between microcephaly, Zika virus infection, and other risk factors in Brazil: final report of a case-control study. 38
29242091 2018
518
[Anaphylaxis related to measles, mumps, and rubella vaccine in Santa Catarina State, Brazil, 2014 and 2015]. 38
29538498 2018
519
Serological diagnosis of mumps: Value of the titration of specific IgG. 38
28126326 2018
520
Immunity against measles, mumps, rubella, varicella, diphtheria, tetanus, polio, hepatitis A and hepatitis B among adult asylum seekers in the Netherlands, 2016. 38
29454516 2018
521
Evaluation of a Mobile Phone-Based Intervention to Increase Parents' Knowledge About the Measles-Mumps-Rubella Vaccination and Their Psychological Empowerment: Mixed-Method Approach. 38
29514772 2018
522
[Measles are eliminated in Denmark]. 38
29559077 2018
523
Serological survey of measles immunity in the Czech Republic, 2013. 38
29684293 2018
524
Vaccination coverage among foreign-born and U.S.-born adolescents in the United States: Successes and gaps - National Immunization Survey-Teen, 2012-2014. 38
29483032 2018
525
Incomplete childhood immunization with new and old vaccines and associated factors: BRISA birth cohort, São Luís, Maranhão State, Northeast Brazil. 38
29538497 2018
526
Pediatric Resident Education and Preparedness Regarding Vaccine-Preventable Diseases. 38
28825317 2018
527
The impact of immunization programs on 10 vaccine preventable diseases in Italy: 1900-2015. 38
29428176 2018
528
Disease burden of psittacosis in the Netherlands. 38
29361998 2018
529
Low intrathecal antibody production despite high seroprevalence of Epstein-Barr virus in multiple sclerosis: a review of the literature. 38
29098417 2018
530
The role of extended and whole genome sequencing for tracking transmission of measles and rubella viruses: report from the Global Measles and Rubella Laboratory Network meeting, 2017. 38
29424220 2018
531
Clinical profile of congenital rubella syndrome in Yogyakarta, Indonesia. 38
29068106 2018
532
A novel cell-based high throughput assay to determine neutralizing antibody titers against circulating strains of rubella virus. 38
29191395 2018
533
Microcephaly in Piauí, Brazil: descriptive study during the Zika virus epidemic, 2015-2016. 38
29412347 2018
534
Mumps: An Emergency Medicine-Focused Update. 38
29110978 2018
535
The pathogenesis of microcephaly resulting from congenital infections: why is my baby's head so small? 38
28980148 2018
536
Mumps clinical diagnostic uncertainty. 38
28633302 2018
537
Hearing-loss-associated gene detection in neonatal intensive care unit. 38
28093008 2018
538
Blueberry muffin rash secondary to hereditary spherocytosis. 38
29554165 2018
539
Investigating the assumptions of the self-controlled case series method. 38
29094391 2018
540
IgG antibody prevalence suggests high immunization needs in newcomers to Luxembourg, 2012. 38
29306505 2018
541
Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial. 38
29395526 2018
542
Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine. 38
29317117 2018
543
Public health significance of immunization and epidemic occurrence of measles. 38
29549689 2018
544
Immunization Practices of U.S. Obstetrician/Gynecologists for Pregnant Patients. 38
29246674 2018
545
Use of electronic immunization registry in the surveillance of adverse events following immunization. 38
29412373 2018
546
Rubella immunity and serum perfluoroalkyl substances: Sex and analytic strategy. 38
30248109 2018
547
Treatment of Epithelial Downgrowth Masquerading as Unilateral Hypopyon Uveitis in a HLA-B27+ Individual. 38
27598054 2018
548
A cross-sectional study to assess the awareness and practices related to adult immunization among nursing students in a metropolitan city. 38
30505857 2018
549
Characterization of Vaccination Policies for Attendance and Employment at Day/Summer Camps in New York State. 38
29325483 2018
550
Different composition of intraocular immune mediators in Posner-Schlossman-Syndrome and Fuchs' Uveitis. 38
29944680 2018
551
Immunopathology of Virus-Induced Anterior Uveitis. 38
29543540 2018
552
Seroprevalence data at a private teaching hospital in Kenya: An examination of Toxoplasma gondii, cytomegalovirus, rubella, hepatitis A, and Entamoeba histolytica. 38
30325924 2018
553
Reporting of adverse events following immunizations in Ghana - Using disproportionality analysis reporting ratios. 38
29172941 2018
554
Measles and Rubella Global Strategic Plan 2012-2020 midterm review. 38
29307367 2018
555
Measles and Rubella Global Strategic Plan 2012-2020 midterm review report: Background and summary. 38
29307368 2018
556
Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III randomized study. 38
29277353 2018
557
2017 Measles-Rubella Vaccination Campaign in India. 38
29619155 2018
558
Measles and rubella eradication. 38
29183733 2018
559
Congenital rubella syndrome: A brief review of public health perspectives. 38
29512566 2018
560
Evaluation of nationwide supplementary immunization in Lao People's Democratic Republic: Population-based seroprevalence survey of anti-measles and anti-rubella IgG in children and adults, mathematical modelling and a stability testing of the vaccine. 38
29596472 2018
561
Head-to-head immunogenicity comparison of Edmonston-Zagreb vs. AIK-C measles vaccine strains in infants aged 8-12 months: A randomized clinical trial. 38
29289382 2018
562
Use of the revised World Health Organization cluster survey methodology to classify measles-rubella vaccination campaign coverage in 47 counties in Kenya, 2016. 38
29965975 2018
563
Case-based surveillance of measles in Sicily during 2012-2017: The changing molecular epidemiology and implications for vaccine strategies. 38
29617454 2018
564
Rubella Retinopathy. 38
30578518 2018
565
Rubella in Poland in 2016 38
30394039 2018
566
Rubella Vaccine-Reply. 38
29159369 2018
567
Reconstructing the transmission dynamics of rubella in Japan, 2012-2013. 38
30332469 2018
568
Rubella Vaccine-A Tale of Appropriate Caution and Remarkable Success. 38
29159364 2018
569
Myelin Oligodendrocyte Glycoprotein-Independent Rubella Infection of Keratinocytes and Resistance of First-Trimester Trophoblast Cells to Rubella Virus In Vitro. 38
29300335 2018
570
Both Sphingomyelin and Cholesterol in the Host Cell Membrane Are Essential for Rubella Virus Entry. 38
29070689 2018
571
Hospital based surveillance of congenital rubella syndrome cases in the pre-vaccine era in Amhara Regional State, Ethiopia: A base line information for the country. 38
30419036 2018
572
[Development of a test kit for the detection of IgG-antibodies to individual antigens of Rubella virus by immunoblotting (Western blot).] 38
30776204 2018
573
Peptide Sharing Between Viruses and DLX Proteins: A Potential Cross-Reactivity Pathway to Neuropsychiatric Disorders. 38
29618965 2018
574
Substrate specificity of plant nitrilase complexes is affected by their helical twist. 38
30417123 2018
575
Pediatric reference intervals for 29 Ortho VITROS 5600 immunoassays using the CALIPER cohort of healthy children and adolescents. 38
28723610 2018
576
Variation in Splicing Efficiency Underlies Morphological Evolution in Capsella. 38
29275992 2018
577
Infectious causes of microcephaly: epidemiology, pathogenesis, diagnosis, and management. 38
28844634 2018
578
Utility of routine urine CMV PCR and total serum IgM testing of small for gestational age infants: a single center review. 38
28803228 2018
579
Association between paternal smoking at the time of pregnancy and the semen quality in sons. 38
30462692 2018
580
Genome-wide identification and characterization of CONSTANS-like gene family in radish (Raphanus sativus). 38
30248137 2018
581
Hydrocephalus associated to congenital Zika syndrome: does shunting improve clinical features? 38
29086073 2018
582
[Response capacity and challenges of the Cuban health system against communicable diseasesCapacidade de resposta e desafios do sistema de saúde cubano contra doenças transmissíveis]. 38
31093059 2018
583
[Countermeasures for rubella outbreak among adults in Sumida city from April 2013 to March 2016]. 38
29618702 2018
584
Current status of vaccines in psychiatry-A narrative review. 38
29476951 2018
585
Polymorphisms in the Wilms Tumor Gene Are Associated With Interindividual Variations in Rubella Virus-Specific Cellular Immunity After Measles-Mumps-Rubella II Vaccination. 38
29253144 2018
586
The MRZ reaction helps to distinguish rheumatologic disorders with central nervous involvement from multiple sclerosis. 38
29386006 2018
587
Zika Virus as a Possible Risk Factor for Autism Spectrum Disorder: Neuroimmunological Aspects. 38
30630174 2018
588
Sleep EEG of Microcephaly in Zika Outbreak. 38
29562870 2018
589
Review for Disease of the Year: Treatment of Viral Anterior Uveitis: A Perspective. 38
30096015 2018
590
Vaccination Practices in Pediatric Dialysis Patients Across Europe. A European Pediatric Dialysis Working Group and European Society for Pediatric Nephrology Dialysis Working Group Study. 38
29232664 2018
591
Systematic detection of positive selection in the human-pathogen interactome and lasting effects on infectious disease susceptibility. 38
29799843 2018
592
Isolation of infectious Zika virus from a urine sample cultured in SIRC cells from a patient suspected of having rubella virus. 38
29557985 2018
593
Rubella vaccination in India: identifying broad consequences of vaccine introduction and key knowledge gaps. 38
29198212 2018
594
Mumps in Poland in 2016 38
30394050 2018
595
Infectious diseases in Poland in 2016 38
30111085 2018
596
Mumps Outbreak in a Highly Vaccinated University-Affiliated Setting Before and After a Measles-Mumps-Rubella Vaccination Campaign-Iowa, July 2015-May 2016. 38
29020324 2018
597
Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study. 38
29902133 2018
598
Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study. 38
30118386 2018
599
Application of a mixture model to assess the effect of measles-mumps-rubella vaccine on the mumps epidemic in children from kindergarten to early school age in Jiangsu Province, China. 38
29792546 2018
600
Recommendation of the Advisory Committee on Immunization Practices for Use of a Third Dose of Mumps Virus-Containing Vaccine in Persons at Increased Risk for Mumps During an Outbreak. 38
29324728 2018
601
Trend of vaccine preventable diseases in Iraq in time of conflict. 38
31037190 2018
602
Rubella natural immunity among adolescent girls in Tanzania: the need to vaccinate child bearing aged women. 38
29298693 2018
603
Diagnosis of rubella virus using antigen-conjugated Au@Pt nanorods as nanozyme probe. 38
30197515 2018
604
Prevalence of Rubella Antibodies Among Children in the Democratic Republic of the Congo. 38
28746265 2018
605
Congenital rubella syndrome: an unusual cause of neonatal fulminant hepatic failure. 38
28678001 2018
606
Safety of vaccines that have been kept outside of recommended temperatures: Reports to the Vaccine Adverse Event Reporting System (VAERS), 2008-2012. 38
29248264 2018
607
Adverse events after vaccination among HIV-positive persons, 1990-2016. 38
29920551 2018
608
Spontanuous Demand For Meningococcal B Vaccination: Effects On Appropriateness And Timing. 38
29927693 2018
609
Response to third rubella vaccine dose. 38
29771601 2018
610
The immunization status of children with chronic neurological disease and serological assessment of vaccine-preventable diseases. 38
29624477 2018
611
Safety of live vaccines on immunosuppressive or immunomodulatory therapy-a retrospective study in three Swiss Travel Clinics. 38
29394383 2018
612
[Analysis of the territorial patterns of the life contexts of children up to 6 years of age and their potential influence on the coverage of immunization programs in Chile]. 38
30020363 2018
613
Socioeconomic Status Is Associated With Antibody Levels Against Vaccine Preventable Diseases in the Netherlands. 38
30140666 2018
614
Building capacity for active surveillance of vaccine adverse events in the Americas: A hospital-based multi-country network. 38
28803714 2018
615
MMR2 vaccination coverage and timeliness among children born in 2004 - 2009: a national survey in Saint Lucia, 2015. 38
31093104 2018
616
One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life. 38
29224964 2018
617
The Role of Humor in Messaging about the MMR Vaccine. 38
29757123 2018
618
Measles and rubella elimination: learning from polio eradication and moving forward with a diagonal approach. 38
29037086 2017
619
Do patients with schizophreniform and bipolar disorders show an intrathecal, polyspecific, antiviral immune response? A pilot study. 38
29212505 2017
620
Infection of iPSC Lines with Miscarriage-Associated Coxsackievirus and Measles Virus and Teratogenic Rubella Virus as a Model for Viral Impairment of Early Human Embryogenesis. 38
29043768 2017
621
Measles, Rubella and Varicella IgG Seroprevalence in a Large Refugee Cohort in Germany in 2015: A Cross-Sectional Study. 38
28875465 2017
622
Assessment of National Public Health and Reference Laboratory, Accra, Ghana, within Framework of Global Health Security. 38
29155650 2017
623
[Genetic characterization of rubella virus isolated in Guizhou Province from 2012 to 2015]. 38
29262493 2017<